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ABSTRACT
Infectious diseases that spread from person-to-person and continent-to-continent are a
cause for concern for any health entity. One such disease is malaria, a mosquito-borne infection
instigated by the protozoan parasite, Plasmodium falciparum. Hundreds of millions of people
are affected annually and it is responsible for nearly 1 million deaths. It is the most fatal species
causing malaria and proliferates in human red blood cells with a life cycle occurring every 48
hours. At this time, the parasite’s late stage form or schizont bursts from the erythrocyte
releasing immune-inducing particles and infective forms (merozoites) into the bloodstream. The
merozoites go on to infect other red blood cells as human immunity leads to fever. Fever is a
hallmark symptom of malaria and effectively inhibits the growth of late stage parasites.
Plasmodium still manages to complete its life cycle as early stages or rings are not affected by
febrile temperatures. It is this facet of parasite biology that prompts our research into identifying
genetic factors associated with fever.
The parasite’s response under elevated body temperature may offer further insight into its
adaptive mechanism. A heat shock assay was developed in order to simulate fever in vitro.
Mutant parasite cultures were subjected to 41°C for 8 hours and returned to normal body
temperature or 37°C for the remainder of the life cycle. The piggyBac mutagenesis system
allows for the evaluation of phenotypes associated with a particular genotype as the transposon
inserts randomly into the gene. This often leads to changes in function that may cause delays in
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invasion or attenuation of growth. Determining the genes responsible for these phenotypes
would be a great advantage to the field of drug discovery.
Collaborative efforts to develop vaccines and new antimalarial drugs are underway as
resistance to current methods of treatment is on the rise. Such circumstances require new
technologies for detecting novel drug targets or pathways in the parasite that can be significantly
affected by these therapeutics. QISeq is a next generation sequencing tool that identifies genes
with a particular phenotype that may alter intraerythrocytic development of P. falciparum. This
technique was utilized in our study to confirm the heat shock phenotype with a high-throughput
approach. The genomic DNA of pooled parasite cultures was sequenced to reveal those mutants
sensitive and/or resistant to febrile temperature exposure. Through bioinformatics analyses,
functional associations between genes can be made that lead to biological pathways of interest
for therapeutic research.
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CHAPTER ONE:
INTRODUCTION

Background
Malaria: Defining “Bad Air”
Before modern medicine and technological advances established the etiology of a
particular illness, many diseases were thought to be caused by humors or “something in the air.”
Hence, the root of the word for malaria as translated in Italian to mean bad air. We now know
that malaria is caused by the bite of an infected A nopheles mosquito carrying parasites of the
phylum Apicomplexa and genus Plasmodium. It is not the air itself that transmits the infection,
but tropical climates and standing water that allow for the propagation of these insect pests that
do. Once the protozoan parasites enter the human body from the female mosquito host, they
cause a wide range of molecular and cellular changes.

Geographic Distribution of Human Malarias
At present, there are five species of malaria that infect humans, Plasmodium falciparum P.
vivax, P. malariae, P. ovale, and P. knowlesi. Malaria is a serious infectious disease and is
responsible for nearly one million deaths and hundreds of millions of infections worldwide per
year. The World Health Organization estimates that of the 198 million cases of malaria in 2013,
approximately 128 million infections are caused by P. falciparum, the deadliest form of the
disease, in sub-Saharan Africa alone (Figure 1.1, [44]). This global threat affects people in many
1

different regions of the world from the Americas, Africa, to the Mediterranean, Asia and so on,
where the greatest risk of death is in children under five and pregnant women. In the United
States, sporadic outbreaks of malaria occur in Florida and Southern California and are caused by
P. vivax as well as travelers from endemic countries.

Life Cycle of Plasmodium
Growth and development of protozoan parasites in the genus, Plasmodium, are quite
complex. There are typically two hosts involved in this process, the mosquito vector and a
vertebrate animal (Figure 1.2, [9]). The sexual cycle occurs in the mid-gut of the female
A nopheles mosquito, where an infective form known as the sporozoite migrates to the salivary
gland in preparation for a blood meal (12, 14). This process begins with the uptake of male and
female gametocytes from an infected human host. According to Touray and others, fertilization
occurs in the mosquito midgut, producing oökinetes that move through the midgut and develop
into oocysts (43). These oocysts divide and mature into sporozoites that move through the
hemocoel toward the salivary glands after nearly nine days (14, 43). Once the sporozoite is
injected into the human host, it makes its way to the liver, undergoes differentiation (in the preerythrocytic or intrahepatocytic cycle), and seeks out red blood cells to invade [12].
From this point on, the asexual cycle has begun and the parasite uses up host cell
nutrients, multiplies, and re-invades. During the blood stage (which takes approximately 48
hours to complete in the case of P. falciparum), the parasite starts as a ring-shaped object in the
erythrocyte, then grows as a single nucleus-containing trophozoite, and ultimately differentiating
into a multi-nucleated schizont before rupturing to release invasive merozoites (16). These
invading cells known as merozoites are released and attach themselves to waiting erythrocytes, a
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mechanism that has been well-studied. Within the merozoite are apical organelles, specific to
apicomplexan parasites, such as micronemes, rhoptries, and dense granules that are responsible
for invasion. Once in contact with the red blood cell surface, the merozoite reorients itself such
that its apex is joined to the erythrocyte membrane (13). This causes invagination of the red
blood cell, allowing the merozoite to invade and elude detection by the host’s immune system.
Invasion is largely facilitated by a tight junction that forms between the parasite and the
erythrocyte. Since the P. falciparum genome and transcriptome were published, information on
the genes and proteins involved in this process has been revealed. Upon entry, the outer coat of
the merozoite is removed by proteases that also detach ligands responsible for further traversal of
the parasite into the host cell while forming a parasitophorous vacuole (12). The Plasmodium
parasite contains surface proteins and ligands that bind to receptors on red blood cells deemed
suitable for invasion. The micronemal protein known as the erythrocyte binding antigen-175
(EBA-175) is part of the Duffy binding-like family of proteins that facilitates invasion through
binding of the glycophorin A receptor on the erythrocyte in the presence of sialic acid (17, 25).
Another protein that mediates invasion is one involved in motility, GAP45 or glideosome
associated protein 45 (39). This protein is present in the latter stages of the erythrocytic cycle,
specifically the schizont phase leading towards merozoite egress. GAP45 undergoes methods of
post-translational modification including myristoylation, palmitoylation, and even
phosphorylation during schizont maturation and cell division (39). The plasma membrane
surrounding each merozoite associates with GAP 45 and the inner membrane complex whilst
aiding schizont rupture (39). Ultimately, invasion is a multi-tiered, cyclical process involving
the expression of genes necessary for continued growth and development of the parasite. The
transmission of malaria continues when another mosquito pierces the skin and takes up the
3

waiting gametocytes in the blood of the host to start the cycle over again. Drug and vaccine
development target these three phases of the parasite life cycle, which contribute to the clinical
manifestations of malaria.

Signs and Symptoms of Malaria
Any pathogen that invades the human body causes a physical and cellular change in
efforts to rid the system of foreign invaders. Human immunity is designed to recognize non-self;
however, Plasmodium parasites exploit that and in doing so, cause many deleterious side effects
to the host. This can be complicated further in immuno-compromised individuals or in those
patients with co-infections, such as HIV and malaria. In uncomplicated malaria, symptoms of
headache, nausea, muscle/joint pain, malaise, and fatigue appear before the classic symptom of
fever (6). Severe malaria is characterized by signs of high anemia, metabolic acidosis, organ
failure, cerebral malaria, seizures, coma and eventually death (6, 31). Anti-malarial therapy is
necessary before it reaches a fatal point, although treatment of severe malaria may still lead to
blindness and other neurological disorders such as speech impairment and deficient motor
function (6). These clinical outcomes are additionally explained by the genetics and cellular
biology of the host-parasite interaction. For the purposes of this study, we focus our attention on
the erythrocyte stage and the molecular mechanisms as well as intrinsic factors that may alter
Plasmodium development. This may provide clues to understanding what affects gene
expression in the parasite and the host response to disease persistence.
Anti-malarial Drugs: Treatment & Prophylaxis
Currently, no vaccine exists to prevent infection and widespread resistance to antimalarial drugs is emerging as a major threat to elimination efforts, supporting the need for new
4

drug discovery and development projects. At present, drug targets are largely aimed at the
intraerythrocytic or blood stage phase of development. Chloroquine was used as the front line of
treatment for P. falciparum malaria, but resistance has made monotherapies obsolete and
combination drugs a requirement (19). Artemisinin, like chloroquine interrupts the production of
hemozoin in the parasite’s food vacuole, affecting further development (32). ACTs or
artemisinin combination therapies have been more effective since they have different
mechanisms of action and target multiple cells/pathways (19). In addition to chloroquine, other
quinine derivatives exist such as mefloquine, amodiaquine, piperaquine, primaquine,
halofantrine, and lumefantrine to name a few (24). These anti-malarial drugs are largely
involved in affecting the parasite’s ability to digest hemoglobin. When combined with
derivatives of artemisinin, they are effective in killing erythrocytic stages of P. falciparum and
reducing parasitemia (32). Antifolate drugs like sulfadoxine-pyrimethamine and proguanil target
folic acid synthesis in the parasite’s cytosol and atovaquone, which inhibits mitochondrial
processes can be used in conjunction with proguanil to affect multiple sites (5, 19, 24).
Mechanical and chemical means of prophylaxis have been suggested as ways to prevent malaria
transmission and re-infection. These include, but are not limited to: insecticide-treated bed
nets/tarps, mosquito control through indoor spraying, vitamin supplementation and (IPTp)
intermittent preventive therapy in pregnancy using sulfadoxine-pyrimethamine (19).

Drug Discovery
The sequencing and annotation of the P. falciparum genome helped support more
advanced studies in malaria biology, facilitating transfection and gene knockout strategies to
characterize important genes. These tools are considered to be important in validating drug
5

targets, especially by introducing resistance alleles in otherwise sensitive parasites. Two major
parts of drug discovery are target identification and validation for which phenotype screens are
effective in determining leads (22). Potential hits or inhibitory molecules detected from this
strategy typically have antagonistic effects on the intracellular target (organelle, metabolism, cell
viability, etc.) so that novel antimalarials are found [22]. Much of malaria biology is still not
well understood, although the search for new drugs continues as more studies are conducted to
identify important metabolic processes and pathways. Clinical disease results from recurrent
asexual development of the malaria parasite in the blood stage, which depends on a progressive
pattern of gene expression widely believed to be embedded into the genome. It is thought that
such activities of regulating transcription and translation are vital for P. falciparum and necessary
for efficient growth of the parasite.

Fever Patterns in Malaria
A hallmark symptom of malaria is the regular cycles of fever and chills known as
paroxysms. Plasmodium falciparum is a tertian malaria where every 48 hours the fever episode
coincides with completion of the asexual cycle where schizont rupture in a process referred to as
egress to release the invasive merozoite stages that initiate another round of intraerythrocytic
asexual development. Along with the merozoites all of the debris from parasite development,
including hemozoin and LPS-like molecules, are released into the infected person’s blood (23,
46). This bursting also denotes that the parasitemia or percentage of parasites in the blood has
increased exponentially. According to Kwiatkowski & Greenwood, the fever cycle has been
known to synchronize the protozoan population, whereby young parasites are selected to
continue growth and replication (26). This discovery has led to the development of antipyretics,
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which may reduce disease progression when used in combination with artemisinin and its
derivatives (27). Other Plasmodium species promote fevers that occur every 72 hours (quartan
malaria) as seen in P. malariae. During fever, where temperatures fluctuate between 37°C and
40°C, the sleep patterns of infected humans are disturbed further affecting synchronicity and
parasite transmission (26).
Release of toxins such as the hemozoin and LPS-like molecules from the bursting
schizont stimulates innate immune response mechanisms. In malaria pathogenesis, these host
immune responses include proinflammatory cytokines, such as TNFα, IL-1, IL-6, IL-12, and
complement factor 5a promote the fever associated with the paroxysm (36, 41). Pathogenassociated molecular patterns or PAMPs are activated by the LPS-like molecules, which have
glycosylphosphatidylinositol (GPI) membrane anchors, to elicit cytokine and nitric oxide
synthase response [41]. The host cells contain damage-associated molecular patterns such as
heme, uric acid, and microvesicles that interact with these PAMPs (15). Fever causes cellular
and molecular changes that can be linked to transcriptional overexpression of genes exposed to
heat shock (36).

Heat Shock Proteins in Malaria
Fever is part of the human innate immune response since prolonged periods of elevated
temperature can be harmful to microbes and can have a significant effect on the malaria parasites,
too. The human immune-induced fever heat shock is not the only time P. falciparum experiences
a drastic temperature fluctuation except when the parasite shifts from the mosquito host to the
human and back (21). Elevated body temperature results in the unfolding of proteins, cell cycle
arrest, and structural changes in the cell membrane. Consequently, episodes of elevated
7

temperature are associated with concomitant ‘parasite defense’ responses that are seen as
variations in Plasmodium gene expression. Molecular chaperones, specifically heat shock
proteins (HSP), help to fold these proteins and prevent aggregation that can reduce cell viability
[34, 35]. Previous studies comparing in vitro culturing at 37°C and 41°C, has revealed a set of
genes that may be involved in temperature regulation. Proteins encoded by these genes
participate in various biological processes such as stress response, DNA repair, trafficking,
protein secretion, transcription, signal transduction, and cytoskeleton formation to name a few
(35). They were compiled from gene expression data and comparative sequence analysis so that
Hsp70, Hsp90 and others display increased expression (35). These proteins are necessary for
parasite survival during febrile episodes, where the heat shock response induces transcription and
alters protein synthesis (30).
The six Hsp-70s that occur in P. falciparum are responsible for protein transport or
trafficking as well as folding and they are located in various parts of the cell (42). According to
Shonhai, these Hsps may be drug targets that inhibit the import and export of malarial proteins to
the erythrocyte surface or disrupt the interaction with Hsp90 or Hsp40 (42). There are four
classes of Hsp40s in the 49-member family of which some contain the PEXEL or Plasmodium
export element sequence and are expressed early in development (37). Under febrile
temperatures, Hsp40s are also upregulated like Hsp90s which modulate gene expression during
development, heat shock factors, and the activities of protein kinases (7). Common inhibitors to
Hsp70 and its co-chaperones Hsp40 and Hsp90 include pyrimidinones, ATP analogues such as
napthoquinones and tetraprenylated alkaloids, and the antibiotic Geldanamycin (21).
Pyrimidinones alter the role of Hsp70s in presenting antigens on the cell surface and in
stimulating NFκB signaling, while ATPase activity and protein aggregation is inhibited by “ATP
8

mimics” (21). Geldanamycin blocks Hsp90 binding and can be effective in attenuating P.
falciparum growth. Environmental stressors like heat and responses to nutrient starvation both
employ the use of such chaperones to protect the parasite, and can thus be sites for new
antimalarial drugs.

Other Stress Responses in Plasmodium
As previously discussed, heat shock proteins are activated when a rise in temperature is
experienced. This can lead also to reduced protein ubiquination, decreased transcriptional
regulation and DNA replication. It has been reported that Hsp90 plays a role in early stage
development from ring to trophozoite during cyclical fever episodes and is necessary for
adaption to heat stress (33).
Oxidative stress also induces cellular changes in P. falciparum. This protozoan is capable
of siphoning antioxidants from the host in conjunction with its own redox system, and slows its
life cycle by 4 hours in the presence of increased oxygen (33). Such a variation in the
environmental conditions of malaria resulted in down-regulation of genes involved in amino acid
metabolism and glycolysis, as well as an up-regulation of heat shock and DNA repair proteins.
Nutritional stress or a paucity of sufficient amounts of isoleucine causes phosphorylation events
during intra-erythrocytic growth that affects the expression of protein kinases important for
signaling (33).

Transcription and Gene Expression in Eukaryotes
The regulation of transcription is necessary for proper growth of P. falciparum. The
expression of genes in any organism involves a multi-step process of transcription, translation,
9

and posttranslational modifications. RNA transcription involves the use of promoters, three
types of RNA polymerases, and a host of other transcription factors. The asexual stages of
Plasmodium from ring to trophozoite to schizont (G1/G2/M) occur inside the red blood cell,
during which genes are transcribed in a rolling cascade (8, 28). Currently, most attention in
malaria research is focused on transcriptional regulators of gene expression and a lot of our
understanding of P. falciparum gene regulation still comes from studies on genes involved in
antigenic variation or var, which undergo differential expression events to evade the immune
system and persist in the host (40). Most of these studies support regulation of transcription in P.
falciparum as essential in determining when genes are activated or not. However, posttranscriptional modifications may also alter the expression of genes and in many eukaryotes
messenger RNA (mRNA) stability controlled through mRNA decay pathways determines the
amount of transcripts available for translation (45). Such regulatory mechanisms serve to
stabilize mRNA and involve adding a 5’ cap and poly-adenylated tail or conversely removing
them to degrade transcripts (18, 45).
Each process involves various checkpoints and regulatory steps that control the timing
and rate of expression. The eukaryotic system is very complex, engaging many proteasome and
exosome associated processes, to turn on and off different genes at different times. This speaks
to the multi-functionality of cells in eukaryotes that depend on timing and transcript levels to
generate a viable gene product. In many eukaryotes, the CCR4-NOT complex and other
interacting partners are critical functional components regulating this mRNA stability. The
processes regulated by the CCR4-NOT complex are poorly understood in P. falciparum and this
is the focus of my research plan.
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CCR4-NOT Complex
The CCR4-NOT complex is a eukaryotic gene regulatory system best characterized in
yeast, yet poorly understood in Plasmodium falciparum. The CCR4-NOT complex is involved
in multiple aspects of mRNA metabolism and consists of five NOT proteins among other
subunits. NOT stands for Negative On TATA-less promoters, which in yeast act as
transcriptional repressors (11). Proteins of the NOT family are responsible for blocking the
attachment of TATA binding proteins to genes that lack the promoter sequence TATA (1). The
single NOT1 protein of Saccharomyces cerevisiae is essential and cannot be knocked out as this
would lead to a reduction in growth and loss of viability for yeast (11). In P. falciparum,
PF3D7_1103800 is unexpectedly one of two NOT1 proteins that exist (the KO we have already).

PF3D7_1103800 (NOT1) and Comparison to Other Homologs
The NOT1 protein or PF3D7_1103800 is an important feature of the CCR4-NOT
complex. Plasmodium are unusual in that they have two distinct NOT1s that appear to be coexpressed in all stages studied (28). The amino acid sequences of the NOT1 domain were
aligned and examined for conserved regions. Both NOT1 contain binding sites for other
members of the complex on their N-terminal (CCR4 - CAF1) and the C-terminal (NOT2 – 5)
regions, suggesting the second NOT1 (PF3D7_1417200, formally known as PF14_0170) may be
functionally compensating for the PF3D7_1103800 gene disruption.
Further genetic characterization of the PF3D7_1103800 NOT1 would be useful to help
fill a critical gap in our knowledge of parasite growth and development. Unfortunately, the
current technical limitation on P. falciparum gene manipulation severely limits detailed targeted
genetic analysis of this very large gene. In lieu of this, the proposed project will characterize
11

differences between the CAF1 KO phenotype and the PF3D7_1103800 NOT1 KO. In addition, I
will phenotypically screen a mutant library for potential interacting partners. These experiments
may elucidate how the CCR4-NOT complex operates during development through defined
interacting proteins and the significance of its biological function.

Previous studies involving the CAF1 mutant
In the process of a whole genome random insertional mutagenesis of P. falciparum, genes
implicated in nucleic acid metabolism were found to be especially sensitive to disruption leading
to attenuation of asexual blood-stage growth. One of the important regulators of P. falciparum
gene expression we identified was the CAF1 protein of the CCR4-NOT complex. The CCR4associated factor 1 or CAF1 is located on the N-terminal end of the CCR4-NOT complex and is
involved in gene regulation during parasite egress (4). This process occurs in the latter stages of
growth, where a schizont bursts and the invasive merozoites leave the ruins of the red blood cells
to find new erythrocytes to invade. The CAF1 mutant manipulates this bursting, altering the red
blood cell membrane prematurely, and rendering egress incomplete. According to Balu and
others, the merozoites of such schizonts are unable to invade causing an altered state of parasite
development (4). Sequencing the genome of PF3D7_0811300 CAF1 knockout (KO) mutant
detected no SNPs or INDELs to confirm the mutant phenotype was due to disruption of
PF3D7_0811300 (genetic complementation for phenotype rescue was not possible). My
experimental plan will extend this discovery to analyze a KO of PF3D7_1103800 (NOT1),
which is the major scaffold holding together the CCR4-NOT complex.
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piggy Bac Mutagenesis
The piggyBac transposon mutagenesis system provides a powerful tool for disrupting
genes in P. falciparum as well as for rapid stable integration of transgenes for analyzing
expression patterns (2, 3). The system uses a transposable element to create single random
insertional mutations in each organism’s genome, creating multiple distinct mutants that can be
screened for potential drug targets. The piggyback transposase identifies the TTAA sequence in
a genome where it inserts the element as well as duplicates that TTAA site, leading efficiently to
disruption of that locus in the parasite (2). The ability to perform transposon-mediated
insertional mutagenesis in P. falciparum provides a solid platform for carrying out several
genetic analyses not previously available for Plasmodium. When evaluating mutant genotypes
for the rescue of wild-type phenotypes, such transgene analysis is particularly important. Such
innovative technology can be used for phenotypic screens to scan for important genes that
function in parasite survival during intraerythrocytic development.

TraDIS-QISeq System
Transposon-directed insertion-site sequencing or TraDIS can be used to analyze mutant
libraries. TraDIS is a system that can properly identify insertion sites in transposon mutagenesis
through the generation of sequence reads along the insertion (29). Such a method is quite useful
with high-throughput screens needed to determine essential genes and other genetic factors
involved in pathophysiology. Genomic DNA from mutant pools is sent for sequencing, allowing
for the enumeration of insertions that can make the mapping of phenotypes possible. TraDIS can
pinpoint the mutants that survive screening and compare them so that novel drug targets can be
derived (29). In other words, input mutant pools that are exposed to in vitro culture conditions,
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in the case of P. falciparum, are compared with output pools of the mutants that remained after
experimental treatment (10). Attenuated mutants can be identified and a fitness score is provided
as a log2-fold change in sequence reads between the input and output pools covering each
insertion (10). As next generation sequencing improves, designations for these techniques may
also evolve. A modified TraDIS method, known as Quantitative Insertion Sequencing (QISeq),
was developed specifically for the transposon piggyBac in eukaryotic organisms. QISeq
continues to identify and quantify insertions that for a piggyBac mutagenesis study in the mouse
could numerically characterize phenotypic patterns in tissue (38).

Research Focus
Newly sequenced Plasmodium genomes have increased our knowledge of biological
systems and function of malaria parasites. Various gene annotation strategies serve to improve
the flow of information from the laptop to the bench top to treatments; however, many
hypothetical proteins still exist in this haploid parasite limiting our ability to bioinformatically
identify vulnerabilities and critical functional partners in P. falciparum pathways. Functions of
most genes annotated in the genome are unknown but forward genetic analysis will overcome
this obstacle to help link genes with the critical processes that control parasite development,
leading to the discovery of more effective treatments.
Phenotype screens and other methods of genetic validation can be invaluable tools to
improve efforts of target drug discovery that may identify different vulnerable pathways and
develop chemotypes with novel effector mechanisms. My research project used a large-scale
phenotype screen of piggyBac mutants to identify genetic factors associated with altered
sensitivity to heat shock. The factors associated with increased sensitivity to heat shock
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represent potential targets for drug discovery during malaria fever. In addition, my studies have
included the functional characterization of NOT1 in erythrocytic stages of P. falciparum, which
is a component of the putative major regulatory complex, CCR4-NOT.
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Figure 1.1: Global Malaria Transmission. This map shows the transmission of malaria
as of 2013 with the darker shaded areas containing the most cases of the disease1. Image
provided by http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/.

1

Reprinted from World Malaria Report 2014, WHO, Introduction, page No. 2, (2014).
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Figure 1.2: Plasmodium sp. Life Cycle. Malaria subsists in a mosquito host for sexual
replication and in the human during asexual reproduction. Image provided by
http://www.cdc.gov/dpdx/malaria/index.html.
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CHAPTER TWO:
A PHENOTYPIC SCREEN OF PLA SMODIUM
FA LCIPA RUM PIGGY BA C MUTANT CLONES TO IDENTIFY GENETIC
FACTORS LINKED TO HEAT STRESS RESPONSE

Introduction
Malaria is a devastating disease that claims the lives of millions worldwide. Nearly, 3.2
billion people from 97 different countries remain at risk and those with the greatest risk often
have the least access to medical treatment and testing services (18). Since its discovery in 1880
by Charles L. A. Laveran, ways to end disease transmission have been the top priority (4). Once
the vector of transmission was found to be the A nopheles mosquito, elimination of the insect and
its reservoirs were needed. Throughout the past century, mosquito spraying programs and
antimalarial drug distribution have attempted to keep the disease at manageable levels. However,
resistant parasites and even a new species that infects people have emerged to prompt further
study into the biology of malaria and its human host.
The species of Plasmodium that continue their life cycle in humans include: P. falciparum,
P. vivax, P. malariae, P. ovale, and P. knowlesi. Plasmodium knowlesi was initially discovered
in Southeast Asia in the 1930s and uses an intermediate or reservoir host, monkeys, to transmit
its infective form (4, 5). This species was formerly confused with P. malariae, but differs in its
24-hour life cycle (4). Interestingly, P. knowlesi was also used as a pyretic for patients with
syphilis, when the bacterium infected the brain (5). Pyretics or fever-inducing therapeutics have
been utilized for years to combat injury or serious illness. A rise in core body temperature of 1.5
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to 5°C is typically beneficial for infected persons and requires an increase in metabolism to
compensate (6). The severity of the disease may affect the range and duration of febrile
temperatures experienced by the patient and the chances of survival, leading to the use of antipyretics like acetaminophen and ibuprofen (6). However, anti-pyretics present their own
problems in disease treatment by hampering the defense mechanism of the host. A trade-off
must be made between the potential damage to host tissues by fever or the immediate clearance
of harmful pathogens. In the case of Plasmodium sp., the asexual form of the parasite must be
excessive enough (>100 per cubic millimeter of blood) that the fever response takes over,
increasing the number of mononuclear cells such as TNF-producing monocytes (15).
The most lethal of the fearsome five continues to be P. falciparum, yet drug resistance
and new strains with shorter life cycles make these protozoans even more challenging to destroy.
A look into human immunity and the fever response to infection may hold answers to altering
malaria development and ending its proliferation. A patient with clinical manifestations of the
disease display a pattern of fever, chills, sweating, and rigor or shivering (7). Fever onset is a
reaction to the late stages of the parasite, schizonts, being released from the nutrient-depleted and
malformed red blood cell. Elevated body temperature effectively kills any remaining parasites
that are not rings or in the early stages of development and synchronizes invasion (8, 11). In
response to this toxic release of parasite products, monocytes are activated and produce tumor
necrosis factor or TNF (12, 17). Other proinflammatory cytokines like IFN-γ are released that
kill infected erythrocytes through nitric oxide and toxic oxygen pathways (14, 17).
Decline in parasitemia as a result of fever is an obvious benefit. However, the parasite
still manages to escape total destruction and complete its life cycle. Heat shock genes may play a
significant role in proteostasis during febrile episodes, as temperatures of 41°C lead to the
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unfolding of proteins (10). Identifying these and other genes in malaria that adapt to fever would
assist researchers in finding additional candidates for blood-stage drugs. Insertional mutagenesis
is one method by which to conduct such an analysis and the piggyBac system offers just that. By
exposing the piggyBac mutant library to febrile temperature, we may be able to pinpoint genes
that are necessary for parasite development and survival.

Materials and Methods
Plasmodium falciparum Culturing & Maintenance
Standard culturing methods from the Malaria MR4 manual were used. The mutant
library was generated in an earlier study, where the piggyBac transposase was randomly inserted
into the genome of the parasite (1, 2). After transfection with the piggyBac plasmid, drug
selection of the parasite populations occurred through limiting dilution, leaving behind individual
mutants with the piggyBac insertion. Additionally, a complemented parasite from the piggyBac
mutant line (C9 complement) was cultivated with 2 µg/mL Blasticidin as previously described
(3). The P. falciparum wild-type strain, NF54, and mutants were cultured at 37°C with mixed
gas (5% O2, 5% CO2, and nitrogen balance) and 5% hematocrit (O+ blood from the Interstate
Blood Bank) in complete media. Parasites cultured at 41°C also used a tri-gas mix. The culture
media contains RPMI 1640 (Invitrogen) supplemented with 0.5% Albumax II (Invitrogen),
0.25% sodium bicarbonate, and 0.01 mg/mL gentamicin. For the heat shock portion of the
experiment, cultures were synchronized three times with 5% sorbitol (w/v) in the ring stage.
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Heat Shock Assay
Malaria parasite cultures were thawed fresh according to the MR4 method and
resuspended in complete media at 6% hematocrit. Figure 2.1 presents an overview of the
protocol followed for the heat shock assay of the individual mutant screen. After a moderate
parasitemia (1-3%) was reached, the cultures continued to grow in 5 mL flasks with complete
media at a 5% hematocrit. Each mutant clone was exposed to heat shock at 41°C for 8 hours. At
5% parasitemia, cultures were synchronized 3X with 5% sorbitol to ensure that homogeneity of
the culture was achieved. During this procedure, cultures were washed twice with RPMI (after a
15 minute incubation in sorbitol with agitation) and suspended in complete media. The first sync
occurred during the ring stage, 48 hours or 1 cycle later, they were synchronized again and 4-6
hours after that, the final sync took place. The parasitemia was equalized to 3% for all cultures
via microscopy and diluted when necessary. Figure 2.2 depicts the cell morphology of parasite
cultures exposed to heat shock. Afterwards, each heat shock assay was conducted in 96-well
plates with 3-5 piggyBac mutants and 1 NF54 wild-type culture. Based on the modified protocol
from Balu and others (2), 200 µL of each culture was added in triplicate wells to three plates
labeled: T0 (time zero – start of experiment), T30 (thirty hours after start) at 37°C, and T30 (thirty
hours after start with heat for 8 hours) at 41°C. All plates were fixed in 0.05% glutaraldehyde in
preparation for the flow cytometry procedure.

Flow Cytometry
Previous research using flow cytometry on P. falciparum cultures demonstrated that
parasitemia can be estimated (9, 13). These methods were adapted for our work and are briefly
described here. After fixation in 0.05% glutaraldehyde in PBS, the plates were placed at 4°C for
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1 hour. The supernatant was removed after centrifugation (450 x g for 3 minutes), and the pellet
was incubated in 0.3% Triton-X 100 for 10 minutes. Once permeabilization concluded, the
plates were washed in PBS. Next, there was a one-hour incubation in 0.5 mg/mL RNAse A,
followed by 1 hour of staining with 0.1 mg/mL ethidium bromide both at 37°C. The plates were
centrifuged and the pellet was resuspended in PBS, where it was further diluted in order to be
analyzed by the Accuri C6 Flow Cytometer®. This system uses a 485 nm laser that measures
forward light scatter to count cells and emission signals in the FL1 and FL2 channels (2).
Infected cells were differentiated from un-infected cells by gating, where intense signals were
seen in populations in the FL2 channel for ethidium bromide or DNA stains (Figure 2.3A). In
each well, 50,000 cells were counted and the data was analyzed on CFlow sampler software.

Statistical Analysis
In order to measure variation in growth for the heat shock assay, changes in parasitemia
between 37°C and 41°C were acquired for mutant and wild-type cultures. The average fold
change for each parasite at 37°C was compared with the average fold change in cultures at 41°C
(Figure 2.3B). Data was assembled from a one-way ANOVA of normalized log values and
Dunnett’s multiple comparisons test on Prism software (GraphPad). Statistical significance was
determined for samples with a P-value of 0.05.

Bioinformatics Analyses of piggy Bac Mutants
Using a comparative genomic approach, we can analyze the sequences of many genes
through multiple sequence alignments of P. falciparum and other species. Sequence information
was gathered from the NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and PlasmoDB
27

(http://plasmodb.org/plasmo/) Version 24 databases. The amino acid sequences were put into
databases identifying conserved domains like SMART (http://smart.embl-heidelberg.de) that can
lead to pathway and protein interaction (http://string-db.org) data. Such biological networks can
be analyzed wherein protein domains are weighted with an expectation score that indicates the
likelihood of a particular domain interaction causing certain observed protein interactions (19).
Domains with a higher expectation score would typically provide greater confidence in the
protein interaction that is identified. Also, a previous study using the analysis of domain
interactions can predict protein interactions in P. falciparum (20). Gene ontology or GO
annotations can further reveal functional relationships between protein pairs as noted with this
online application (http://go.princeton.edu/cgi-bin/GOTermMapper). Additionally, a gene
network cluster analysis was conducted using GO terms for the biological process and cellular
compartment of the genes through enrichment mapping in Cytoscape software.

Results
Development of an Individual Heat Shock Screen
Plasmodium falciparum piggyBac mutant parasites were subjected to heat shock stress in
vitro to investigate factors responsible for maintaining growth during fever-like conditions. We
used a piggyBac mutant library to associate altered phenotypic effects of febrile temperature to
specific genotypes. A list of mutants used in the individual screen for the heat shock phenotype
is shown in Table 2.1. The gene ID and description is provided along with their growth
attenuation category at 37°C from previous studies (see also supplementary data in reference 2).
The basis of this analysis began with an earlier published study involving P. falciparum wildtype cultures exposed to hyperthermic temperatures (11). Elevated temperature inhibits growth

28

of the parasite, especially at trophozoite and schizont stages, whereas ring stage parasites survive
at 41°C for up to 24 hours. Since there is not a severe drop in ring stage parasite viability until
after 8 hours, our phenotype screen used one round of heat shock for 8 hours at 41°C to simulate
a fever episode, with the cultures returning to 37°C or core body temperature for the remainder
of the life cycle. Under microscopy, the NF54 wild-type and other mutant cultures continue to
grow after heat shock. Yet, there are signs of crisis with less segmentation of the nuclei at the
schizont stage, potentially leading to pyknotic forms.

Heat Shock Induces Growth Changes in piggy Bac Mutants
There were forty-nine P. falciparum mutants randomly selected from the piggyBac
library that underwent individual heat shock treatment. Included in that list of parasites are the
wild-type and C9 complement, which were also assessed for growth changes. Fold change in
parasitemia was compared between cultures at 37°C and those at 41°C, so that a plot shows
parasites on the x-axis and fold change growth on the y-axis (Figure 2.4). Out of the parasites
tested, three were shown to have a statistically significant increase in growth after heat shock.
These mutants are involved with export and trafficking of proteins along with protein
metabolism and modification processes. Twenty mutants had a statistically significant decrease
in growth after heat shock, of which many participate in transcription, nucleic acid metabolism,
and structural maintenance of the cell as seen in Table 2.2. One of these sensitive or decreased
growth mutants was the C9 mutant, a protein phosphatase involved with the cell cycle. The
remaining parasites had no significant change in growth and are largely conserved proteins of
unknown function with some involved in export and signal transduction. The C9 complement
also had no statistical change in growth after heat shock, confirming the rescue of the original or
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wild-type phenotype.

Bioinformatics Reveal Functional Relationships between Mutants in
Individual Screen
The use of bioinformatics techniques allows for comparative sequence analysis of the
mutants used in this phenotype screen. Phylogenetic relatedness and structural characteristics
can be examined. With the GO Term Mapper, certain genes in our library were found to be
associated with numerous biological processes (Figure 2.5). The PfEMP1 family of var genes
are linked to cell adhesion and symbiosis through parasitism as well as cytoadherence.
Cytoadherence is a mechanism in severe malaria where parasitized red blood cells stick or
adhere to the vascular endothelium causing blockage in various organs (16).
In a previous study from the Adams lab, where certain genes from the piggyBac mutant
library were tested for the cytoadherence phenotype, it was revealed that some mutants were
increased in their binding to CHOCD36 cells (unpublished data). Of these, one was an asparagine
rich protein, the C9 or protein phosphatase mutant and mostly conserved proteins of unknown
function. The few mutants that were increased in growth after heat shock are drug transporters, a
PHIST family protein, and a Plasmodium protein of unknown function. The PHIST family
includes exported proteins associated with the PEXEL translocon that interact with the
cytoskeleton of the red blood cell. The mutants that had decreased binding were conserved
proteins of unknown function, one var gene as well as those involved in gene expression
regulation, such as CAF1 and a repressor of MAF1. Interestingly, the mutants with lower
cytoadherence were mostly involved in nucleic acid metabolism, and in the heat shock assay the
decreased growth mutants were also involved in nucleic acid metabolism with others
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participating in trafficking/signal transduction and structural or membrane integrity. The two
other var genes exposed to febrile temperatures showed no statistical change in growth. The
phenotype differences in var genes may have more to do with where the transposon inserted than
with their function. The decreased var mutant has the piggyBac insert in the middle of its
PFEMP domain, while the un-changed vars have the insertion either before or after the PFEMP
domain.
Furthermore, the increased growth mutants are likely associated with metabolic pathways
that participate in transport, export, and oxidative phosphorylation, respectively. Most of the
decreased growth mutants are involved in RNA binding/synthesis, fatty acid metabolism and
signaling, as well as membrane or cellular structure organization. The phylogenetic analysis of
these mutants revealed that the highest degree of conservation lies with other species of
Plasmodium and with the PAT drug transporter, Acyl-CoA synthetase, kelch, splicing factor 3A
subunit 2, and histone methyltransferase in some Apicomplexans such as Cryptosporidium sp.
and Theileria sp. Acyl-coA synthetase is a member of the fatty acid metabolism pathway and is
one of the decreased growth mutant clones that mediates small molecule and lipid metabolism.
Figure 2.6 also provides a network of interacting proteins among the heat shock-treated parasites
and their potential functional partners as well as an enriched network cluster of GO terms.

Discussion
Fever is a natural process by which we fight infection and eliminate the later stages of
malaria parasites. Just as the search for natural products to combat infectious disease is
underway, so to is the work to understand how innate immune mechanisms interrupt or end
intracellular parasite development. The methods by which P. falciparum utilizes to evade

31

immune detection is impressive, yet a more common denominator in this host-pathogen
relationship is how elevated host body temperatures destroy the parasite or disrupt
intraerythrocytic reproduction. Developing a drug to act on mechanisms that enable parasites to
survive cyclical occurrences of 41°C would be quite beneficial. To identify such potential
targets we developed an in vitro heat shock assay based upon previous studies from the Oakley
study that demonstrated increased temperatures inhibit intraerythrocytic growth of P. falciparum
(11). Ring stage parasites survive malaria fever, while later stages (trophozoites and schizonts)
are killed. P. falciparum cultures grown at 41°C for more than 32 hours caused death in 100% of
the parasites. Asynchronous and synchronous cultures exposed to this temperature for 2 – 8
hours, saw reduction in growth correlate to time incubated at 41°C, yet viable parasites remained
(11). With that in mind, we cultured our pooled mutants at 41°C for 8 hours every 48 hours, the
length of the erythrocyte cycle in tertian malarias and returned them to 37°C in between heat
shocks to follow the fever pattern.
The heat shock assay employed here is one way to mimic intracellular fever and identify
those genes which may act synergistically with this process to enhance parasite death. We
discovered that many of these genes function in transport, nucleic acid and protein metabolism as
well as signal transduction (Figure 2.7). The highest cluster frequency was seen in genes
associated with gene expression, RNA metabolism and processing, nucleic acid metabolism, the
macromolecular complex, and cellular nitrogen metabolism. The genes of note had only growth
affects due to heat shock and were increased or decreased significantly after this exposure.
Determining whether these mutants are associated with key functions and gene regulatory
processes can be useful in drug discovery during asexual development for P. falciparum.
Bioinformatics revealed that many of these genes are associated with cell maintenance and
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protein modification, which is to be expected if they are to survive host fever. The members of
the CCR4-NOT transcription complex, CAF1 and NOT1, are also linked to a cluster with RNA
pseudouridylate synthase. The asparagine rich protein is connected with merozoite surface
proteins that also have a link with the transcription factor with AP2 domains (ApiAP2). There
are many Gene Ontology (GO) identifiers associated with increased or decreased sensitivity to
heat shock. As noted earlier, the increased growth mutants or those with decreased sensitivity to
heat shock are structural/membrane proteins, exported proteins, and proteins involved with
protein modification. In addition to the conserved proteins of unknown function that are unchanged after heat shock, there is a gene (PF3D7_0619900) in the spliceosome complex that
interacts with heat shock protein 60. A HSP70 is also found to associate with RNA
pseudouridylate synthase, a protein involved in nucleic acid metabolism. There are additional
genes in the piggyBac mutant library that can be evaluated for the heat shock phenotype. These
and others genes may hold the key to unlocking mechanisms of fever adaptation.
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Figure 2.1: Heat Shock Assay Procedure. This flow chart depicts the setup for the
individual heat shock screen as conducted in 96-well plates. T0 plates represent the ring stage or
beginning of the experiment. T30 plates at 37°C represent the controls and T30 plates at 41°C are
the hyperthermic temperature-treated samples.
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Figure 2.2: Morphology of Cultures under Heat Shock Treatment. Microscopic
view of P.falciparum NF54 WT infected red blood cells. Images are from cultures at 37°C and
41°C for 8 hours.
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Table 2.1: Individual Screen Mutant List. The information provided on their functional
and attenuation categories was adapted from previous work with a genetic screen of these P.
falciparum mutants in reference 2. In the attenuation column, S = severe, N = non-attenuated,
and M = moderate.

PlasmoDB Gene ID

Gene Description

PF3D7_1360200

Conserved protein,
unknown function

PF3D7_1133700

Conserved Plasmodium
protein, unknown
function

PF3D7_1227800

Histone S‐adenosyl
methyltransferase,
putative

PF3D7_0830900

Plasmodium exported
protein, unknown
function
CCR4‐associated factor 1
(CAF1)

PF3D7_0811300

PF3D7_1103800

CCR4‐NOT transcription
complex subunit 1,
putative (NOT1)

PF3D7_0731600

Acyl‐coA Synthetase

PF3D7_1305500

Protein phosphatase,
putative

PF3D7_0622900

Transcription factor with
AP2 domain(s), putative
(ApiAP2)

PF3D7_0402000

Plasmodium exported
protein (PHISTa),
unknown function
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Functional Category
Nucleic acid
metabolism/Nucleic
acid
binding/Transcription
Nucleic acid
metabolism/Nucleic
acid
binding/Transcription
Nucleic acid
metabolism/Nucleic
acid
binding/Transcription
Conserved proteins
with unknown function
Membrane/Structural
proteins, trafficking
and signal transduction
Nucleic acid
metabolism/Nucleic
acid
binding/Transcription
Biochemical
pathways/proteins
metabolism/protein
modification
Cell cycle/Biochemical
pathways/protein
metabolism/protein
modification
Nucleic acid
metabolism/Nucleic
acid
binding/Transcription
Exported Proteins

Attenuation
Category
S

S

S

S

S

S

S

S

S

N

Table 2.1: (Continued)
PlasmoDB Gene ID

Gene Description

Functional Category

PF3D7_1345800

Conserved Plasmodium
protein, unknown
function
Conserved Plasmodium
protein, unknown
function

Conserved proteins
with unknown function

PF3D7_1444100

PF3D7_1328700
PF3D7_1219300
PF3D7_1231800
PF3D7_1475700

PF3D7_1004600

PF3D7_0808700
PF3D7_0619900

PF3D7_1411100.1

PF3D7_0931000

PF3D7_1018300

PF3D7_0416500

PF3D7_1441800

Plasmodium RNA of
unknown function, RUF1
Erythrocyte membrane
protein 1, PfEMP1 (VAR)
Asparagine‐rich protein,
putative
Tubulin epsilon chain,
putative

Conserved Plasmodium
membrane protein,
unknown function
Erythrocyte membrane
protein 1, PfEMP1 (VAR)
Splicing factor 3A subunit
2, putative (SF3A2)

Conserved Plasmodium
membrane protein,
unknown function
Elongation factor Tu,
putative

Conserved Plasmodium
protein, unknown
function
Repressor of RNA
polymerase III
transcription MAF1,
putative
Vacuolar‐sorting protein
SNF7, putative
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Attenuation
Category
N

Biochemical
pathways/protein
metabolism/protein
modification
Plasmodium RNA with
unknown function
Exported Proteins

N

Conserved proteins
with unknown function
Membrane/Structural
proteins, trafficking
and signal transduction

N

Conserved proteins
with unknown function

N

Exported proteins

N

Nucleic acid
metabolism/Nucleic
acid
binding/Transcription
Conserved proteins
with unknown function

N

Biochemical
pathways/protein
metabolism/protein
modification
Conserved proteins
with unknown function

N

Conserved proteins
with unknown function

N

Membrane/Structural
proteins, trafficking
and signal transduction

N

N
N

N

N

N

Table 2.1: (Continued)
PlasmoDB Gene ID

Gene Description

Functional Category

PF3D7_1141900

Inner membrane
complex protein 1b,
putative (IMC1b)
Conserved Plasmodium
protein, unknown
function
Conserved protein,
unknown function
Kelch protein, putative

Membrane/Structural
proteins, trafficking
and signal transduction
Conserved proteins
with unknown function

PF3D7_0521900

PF3D7_1333400
PF3D7_1343700

PF3D7_1122900

Dynein heavy chain,
putative

PF3D7_0404600

Conserved Plasmodium
membrane protein,
unknown function
RNA pseudouridylate
synthase, putative

PF3D7_0511500

PF3D7_1432400
PF3D7_0611800

PF3D7_0206200

PF3D7_0523200

PF3D7_1143500

PF3D7_0601900

PF3D7_1207800

Leucine‐rich repeat
protein (LRR5)
Conserved Plasmodium
protein, unknown
function
Metabolite/drug
transporter ‐
pantothenate
transporter
Conserved Plasmodium
protein, unknown
function
Conserved Plasmodium
protein, unknown
function
Conserved Plasmodium
protein, unknown
function
Conserved Plasmodium
protein, unknown
function
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Attenuation
Category
N

N

Conserved proteins
with unknown function
Membrane/Structural
proteins, trafficking
and signal transduction
Membrane/Structural
proteins, trafficking
and signal transduction
Conserved proteins
with unknown function

N

Nucleic acid
metabolism/Nucleic
acid
binding/Transcription
Conserved proteins
with unknown function
Conserved proteins
with unknown function

N

Membrane/Structural
proteins, trafficking
and signal transduction

M

Conserved proteins
with unknown function

M

Conserved proteins
with unknown function

M

Conserved proteins
with unknown function

M

Conserved proteins
with unknown function

M

N

N

N

N
N

Table 2.1: (Continued)
PlasmoDB Gene ID

Gene Description

Functional Category

PF3D7_1136000

Conserved Plasmodium
protein, unknown
function
Probable protein,
unknown function
(M712)
28S ribosomal RNA

Conserved proteins
with unknown function

PF3D7_1138900

Non‐protein coding,
unspecified product

PF3D7_0211100

Conserved Plasmodium
protein, unknown
function
Conserved Plasmodium
protein, unknown
function
Conserved Plasmodium
protein, unknown
function

PF3D7_1035800

PF3D7_0726000

PF3D7_1459500

PF3D7_0615900

PF3D7_0902200

Serine/threonine protein
kinase, FIKK family
(FIKK9.3)

PF3D7_0400100

Erythrocyte membrane
protein 1, PfEMP1 (VAR)
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Attenuation
Category
M

Conserved proteins
with unknown function

M

Ribosomal RNA

M

Unspecified
product/unknown
transcript
Membrane/Structural
proteins, trafficking
and signal transduction
Conserved proteins
with unknown function

M

Biochemical
pathways/protein
metabolism/protein
modification

M

Biochemical
pathways/protein
metabolism/protein
modification
Exported proteins

M

M

M

M

A

B

Figure 2.3: Flow Cytometric Analysis. A. Parasitized red blood cells were analyzed by
flow cytometry with gating around 30-hour populations or schizonts, the end-point of the assay.
Populations of un-infected cells and ring-stage parasites are also defined. B. Parasitemia was
counted by C6 Flow software for cultures grown at 37°C and 41°C and this calculation was used
in determining the fold change.
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Figure 2.4: Results of Heat Shock Assay. The figure above represents comparative
growth data between cultures grown at 37°C and 41°C. The white bars denote parasites that had
significantly increased growth, the black bars are for parasites with no statistically significant
change in growth, and the grey bars display parasites with significantly decreased growth after
heat shock.
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Table 2.2: Mutants with Heat Shock Phenotype. This table contains a list of the P.
falciparum mutants that were resistant and sensitive to heat shock. These mutants grew normally
at 37°C in a previous growth screen, yet exhibit the heat shock phenotype at 41°C.
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Figure 2.5: Graph of Mutant GO Categories. The GO (Gene Ontology) functional terms
associated with each mutant in the heat shock assay are compared based on whether they are
resistant (increase in growth), no statistical change in growth, or sensitive (decreased growth).
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Figure 2.6: Interaction Network of Heat Shock Mutants. The cluster map above
shows some of the piggyBac mutants used in the individual heat shock assay (highlighted in
yellow) and their predicted functional partners.
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Figure 2.7: Gene Network Enrichment Map. This diagram categorizes the piggyBac
mutants under heat shock by biological process and cellular compartment. GO terms were used
to make the enrichment map above. Red node size corresponds to the number of genes linked to
that GO term. The green edge size corresponds to the number of genes that overlap in GO terms.
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CHAPTER THREE:
A LARGE SCALE PHENOTYPIC SCREEN OF PLA SMODIUM FA LCIPA RUM
MIXED MUTANT POOLS TO IDENTIFY GENETIC FACTORS LINKED TO
HEAT STRESS RESPONSE

Introduction
As one of the three major global health concerns, malaria continues to warrant increased
research and preventative efforts to reduce the burden of disease on endemic regions. Hundreds
of millions of people are infected with malaria with just under one million dying from the disease
annually (21). The region with the greatest number of deaths continues to be the continent of
Africa, where children under the age of 5 make up the majority of mortality reports. The female
anopheline mosquito carries the protozoan parasite responsible for transmitting malaria. One
bite from this insect vector is all it takes to perpetuate the disease as the salivary glands contain
thousands of infectious sporozoites of which only a few (anywhere from 5 to 500 depending on
species) successfully proceed to development [15, 17, 20]. Five species of malaria are capable of
infecting humans; however, P. falciparum is the deadliest malaria parasite and anti-malarial
drugs are in high demand. Such an infection may cause irreparable harm to the human host even
if the outcome is not fatal.
Fever, in particular, is the human body’s method of fighting microbial infections and the
onslaught of other invading pathogens. As a characteristic symptom of malaria, febrile
temperatures can reach 41°C (or ~106°F) and occur intermittently, with some episodes lasting 610 hours [3, 5, 8]. In the case of P. vivax infections, febrile episodes are not as prolonged and
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the rise in body temperature happens under 8 hours (8). In adults, at least 20 – 20,000 parasites
are present in a microliter of blood during the initial febrile state (20). As a quantitative
phenotype, fever can be measured precisely unlike many of the other clinical symptoms
associated with severe malaria, which are often determined retrospectively via surveys of patient
records (10). Parasitemia or the percentage of parasites in the blood is another quantifiable
factor that will aid in understanding the effects of periodic paroxysms. Understanding the
adaptability of the protozoan parasite to evade or survive fever is the impetus for employing heat
shock assays. It is this phenotype that we seek to elucidate through in vitro experiments with
malaria cultures.
Malaria fever results from schizont rupture when various proteins, cellular debris, lipids
(GPI anchors), and hemozoin pigments enter the bloodstream activating tumor necrosis factor
(TNF) from monocytes [13, 20]. The TNF cytokine induces fever and is also responsible for
increased expression of certain ligands necessary for binding in cytoadherence, an effect seen in
cerebral malaria (8, 13, 20). Identifying which proteins are sensitive to high temperatures of
41°C can be useful in proposing new targets for drugs. Heat shock proteins (as the name
suggests) are likely candidates, yet the proteins they associate with have a wide range of
functions. In malaria parasite biology, these include: DNA synthesis, transport, transcriptional
regulation, hemoglobin digestion, RNA processing, cytoskeleton organization, and more;
reflecting the metabolic functional interactions needed for parasite survival during episodes of
fever (11).
An in vitro phenotypic assay developed to screen for altered responses to fever-like
temperatures of individual piggyBac mutant clones was adapted for phenotypic screens of mixed
mutant populations. This phenotypic assay was used to screen complex piggyBac mutant
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populations from a small and large library of P. falciparum mutants. These parallel phenotypic
screens identified a set of genes whose growth was altered by periodic heat shock and may be
essential for parasite adaptation during fever. Carried forward this approach should provide a
comprehensive understanding of how P. falciparum tolerate the stress of fever, which is an
important gap in our knowledge of malaria parasite biology, and may provide the opportunity of
discovering new drug or vaccine targets to combat malaria. More importantly, the forward
genetic screen approach used in this study establishes a methodology that allows for a greatly
enhanced way to functionally profile the P. falciparum genome. Random insertions created by
piggyBac mutagenesis, when combined with the QIseq technique to quantitatively assess
changes under phenotypic selection, provides a much-needed approach for analyzing genotypephenotype relationships.

Materials and Methods
Parasite Culture
All cultures were grown and maintained using standard methods outlined in the Malaria
MR4 manual. The NF54 clone of P. falciparum was used as the parent line for all transfections.
Individual piggyBac mutant clones were obtained by limiting dilution of parasites post-drug
selection (2.5 nM WR99210) and a number of aliquots for each mutant clone were cryopreserved
previously for the project study [1, 2]. The P. falciparum mutants were cultured initially at 37°C
with mixed gas (5% O2, 5% CO2, and 90% nitrogen) and 5% hematocrit (O+ blood from the
Interstate Blood Bank) in complete media. This growth media consists of RPMI 1640 from
Invitrogen supplemented with 0.5% Albumax II (Invitrogen), 0.25% sodium bicarbonate, and
0.01 mg/mL gentamicin. For the heat shock assay, pooled cultures were thawed fresh and grew
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asynchronously until the temperature treatment was applied.

Heat Shock Assay for Pooled Mutants
Figure 3.1A presents an overview of the heat shock assay for the large pool of PB
mutants (the heat shock assays are based on a study by Oakley and others, [13]). Malaria
parasite cultures were thawed and maintained in 5 mL flasks to reach a parasitemia of 3%
parasitemia or at minimum greater than 1%. Flasks were labeled pool 1, pool 2, and pool 3
corresponding to the mutants associated with those groups. At a parasitemia greater than 1%, the
flasks were combined into a master pool and split into 5 – 10 mL flasks. Three flasks were
labeled A, B, and C (triplicate samples) for the heat shock or treatment flasks. The remaining
two flasks were labeled D and E (duplicate controls) and were grown constantly at 37°C. The
treatment flasks were subjected to 41°C for 8 hours, placed back at 37°C and allowed to grow
until the next cycle. The second round of heat shock took place nearly 40 hours later at ring
stage. After 8 hours in an incubator set at 41°C, the flasks were put back at 37°C. This process
repeated until after the third round of heat shock, where the treatment cultures were grown to
more than 5% parasitemia and harvested for gDNA and RNA. The control flasks were only
cultured at 37°C for the duration of the experiment. When the parasitemia reached higher than
2%, the flasks were split to avoid stress by spatial constraints or overgrowth and continued to
grow at 37°C until gDNA and RNA was harvested at the same time as the treatment flasks, at
least eight days later. In addition, mutant clones of pool 1 were screened separately as a single
pool and as individual isolated clones following a similar heat shock protocol, except the
individual clones were exposed to only one round of heat shock and not three.
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A subset of mutants (PF3D7_0523200, PF3D7_1227800, PF3D7_1018300, and
PF3D7_0808700) that exhibited a different phenotype in the pool (with 3 heat shocks) versus its
original phenotype of individual clone screen (with 1 heat shock) were assayed again. Each
mutant clone and one NF54 WT clone were subjected to three heat shocks, only this time each
clone was in its own flask. At a parasitemia equalized to 1%, all cultures were initially grown in
25 – 5 mL flasks. Each clone had three flasks labeled A, B, and C (triplicate samples) for the
heat shock or treatment group and two flasks labeled D and E (duplicate controls) for cultures
grown constantly at 37°C. The treatment flasks were gassed and heat shocked at 41°C for 8
hours, placed back at 37°C and allowed to grow until the next cycle. Sampling occurred after
thirty hours at the late trophozoite/schizont stages and before each heat shock. The second round
of heat shock took place nearly 40 hours later at ring stage. After 8 hours in an incubator set at
41°C, the flasks were put back at 37°C. Before the last heat shock, cultures were brought up to
20 mL in T75 flasks. This process repeated until after the third round of heat shock
(approximately eight days later), where the treatment and control cultures were fixed in 0.05%
glutaraldehyde for flow cytometry.

gDNA Isolation
After the phenotype assay, genomic DNA (gDNA) was collected for Illumina sequencing.
The samples were prepared using the QIAmp DNA Blood Mini Kit (Qiagen) for extracting
gDNA from cell cultures. Alternatively, a modified version of gDNA isolation in Plasmodium
was used to obtain at least 5 µg of sample material. The assayed cultures were centrifuged at
1600 RPM for 3 minutes and the supernatant was removed. The pellet was resuspended in 0.5%
saponin in TEN buffer (0.1M Tris-Cl, pH 8.0; 0.01M EDTA, pH 8.0; and 1M NaCl) and
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vortexed. After transfer to an Eppendorf microcentrifuge tube, the sample was centrifuged at
high speed (10,000 x g) for 3 minutes at room temperature. The supernatant was discarded and
the pellet was washed three times in 1 mL TEN with a 3-minute spin in between. Then, the
pellet was resuspended in TEN buffer with 2% SDS and mixed well, 7.5 M ammonium acetate
was added to the solution, vortexed, and centrifuged at 10,000 x g for 3 minutes at room
temperature. The supernatant is kept and transferred to a new 1.5 mL tube, where an equal
volume of 100% isopropanol is added. The sample is centrifuged at max speed or 14,000 x g for
15 minutes at 4°C. Washes in 70% ethanol and 100% ethanol take place, respectively and the
pellet dries at room temperature until resuspension in water or TE buffer.

RNA Extraction
Once the heat shock assay was complete, RNA was extracted from the pooled cultures
and stored for any further experiments or expression analysis. Using a modified Invitrogen
protocol, infected red blood cell cultures were centrifuged at 12,000 x g for 5 minutes and
washed in 1X PBS. Afterwards, 10% saponin was added and the tube was inverted to allow for
mixing. The sample was incubated at room temperature for 10 minutes. The supernatant was
discarded after centrifugation (12,000 x g for 5 minutes) and the pellet was washed twice with
1X PBS. TRIzol reagent was added to dissolve the pellet through repeated pipetting and a room
temperature incubation for 5 minutes took place as the solution was transferred to another
microcentrifuge tube. Depending on the downstream application, cDNA could be synthesized or
RNA isolation can continue with the addition of chloroform. After a 5-minute incubation, the
sample is centrifuged at 12,000 x g in 4°C for 15 minutes. Only the upper phase or clear
suspension is transferred to another tube as that contains the RNA. The interphase or white
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mixture contains DNA as this separation occurs when chloroform interacts with TRIzol.
Isopropanol is added and mixed by inverting, then incubated for 10 minutes at room temperature.
Once centrifugation at 12,000 x g (4°C) for 15 minutes occurs, the supernatant is removed and
the pellet is washed in 75% ethanol. After a 5-minute spin at 10,000 x g, the supernatant is
discarded and the pellet air dries. The RNA is resuspended in diethylpyrocarbonate (DEPC)treated water and stored at -80°C.

QISeq Illumina Library Preparation
The gDNA extracted from the pooled heat shock screen was sent off to the Wellcome
Trust Sanger Institute in the United Kingdom for quantitative sequence analysis. Their genomic
research facility uses a modified TAIL PCR with Illumina sequencing approach to identify
insertion sites for transposons. This technique is termed QISeq (quantitative insertion site
sequencing), which is a type of TraDIS or transposon-directed insertion-site sequencing, since it
can identify quantitatively each insertion site within mixed populations of piggyBac mutants.
There are four main steps for QISeq: library construction, initial PCR amplification, a second
nested PCR, and the analysis (Figure 3.2). Fragmentation of genomic DNA from the mutant
pool occurs and a poly-A tail is added with custom splinkerette adapters (12, 19). The QISeq
method was developed as a collaboration between Julian Rayner (WTSI) and John Adams
(USF); the excerpt included here is from an unpublished manuscript describing development of
QISeq [4].
“Plasmodium falciparum DNA was quantified using Qubit High Sensitivity assay
according to the manufacturers protocol (Life Technologies Ltd, UK). Between 200 and 500 ng
was sheared using a Covaris E210 Adaptive Focused Acoustics ultrasonicator (LGC Genomics,
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UK) to an average size of 500 bp. The DNA was end repaired, a-tailed and adapter ligated using
a NEBNext DNA Library Prep kit (New England Biolabs (UK) Ltd, UK). Instead of the standard
Illumina adapter a specific adapter containing a 5’ hairpin (Splinkerette adapter) was ligated to
the DNA. Splinkerette adapter: top:
5’-GTTCCCATGGTACTACTCATATAATACGACTCACTATAGGTGACAGCGAGCGCT-3’
bottom: 5’-P-GCGCTCGCTGTCACCTATAGTGAGTCGTATTATAATTTTTTTTTCAAAA
AAA-3’ (4). A 5’ Phosphate group (P) was added to help specific ligation of this adapter to the
DNA library. This Splinkerette adapter was adapted and elongated from (18) to accommodate
Illumina sequencing and multiplexing.
piggyBac insertion sites were acquired from the adapter ligated DNA library using two
nested PCR reactions (PCR1 and PCR2). For this the adapter-ligated library DNA was split in
two to amplify both the 5’ and 3’ end of the piggyBac transposon respectively into two separate
libraries. All PCR reactions were done with KAPA KAPAHiFi HotStart (Anachem Ltd., UK).
PCR1 conditions were as follows (SplAP1:
5’-GTTCCCATGGTACTACTCATA-3’ with PB5-1: 5’-GATATACAGACCGATAAAACACA
TGCGTCA-3’ or PB3-1: 5’-GACGGATTCGCGCTATTTAGAAAGAGAG-3’ for 3’ or 5’
piggybac ends respectively; 18 cycles of PCR; annealing at 63°C; extension at 68°C [to improve
amplification of the AT rich DNA]). These PCR1 reactions were cleaned using 0.8x volume
Ampure XP (Beckman Coulter (UK) Ltd, UK) to remove residual PCR primers. Next a nested
PCR (PCR2) was done for both 5’ and 3’ ends to produce libraries containing only piggyBac
integration sequences (4). PCR2 conditions were as follows
(P7-SplAP2 5’-CAAGCAGAAGACGGCATACGAGATCGGTXXXXTAATACGACTCACTA
TAGG-3’; [XXX is for the reverse complement of the index] with
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PB5-2: 5’-A*ATGATACGGCGACCACCGAGATCTACACCACGCATGATTATCTTTAACG
TACGTCA*C-3’, PB3-2: 5’-AATGATACGGCGACCACCGAGATCTACACATGCGTCAAT
TTTACGCAGACTATC-3’ for 3’ or 5’ piggyBac ends respectively; 12 cycles of PCR;
annealing at 60°C; extension at 68°C). Again the PCR reactions were cleaned using 0.8x volume
Ampure XP (Beckman Coulter (UK) Ltd, UK) to remove residual PCR primers [4].

QISeq Library Quality Control and Sequencing Approach
To determine library yield, 3 individual qPCRs were done on the finished library
using the following forward: PB5pr_seq: 5’-TGATTATCTTTAACGTACGTCACAATATGAT
TATCTTTC-3’ [piggyBac 3’ specific]; PB3pr_seq: 5’-ATGCGTCAATTTTACGCAGACTATC
TTTC-3’ [piggyBac 5’ specific]; PE2.1: 5’-AATGATACGGCGACCACCGAGATC-3’
[Illumina P5 sequence specific]; and reverse (PE2.2:
5’-CAAGCAGAAGACGGCATACGAGAT-3’ [Illumina P7 sequence specific]) primers. qPCR
conditions were standard for the KAPA HiFi qPCR kit (Anachem Ltd., UK) and all products
were quantified relative to the defined standards from the kit [4]. For optimal loading conditions
concentrations of the orientation specific piggyBac primers were used. Generally these were very
similar to the Illumina P5-P7 specific product, whereas the PCR signal for the opposite piggyBac
end always gave a much lower fluorescent signal.
To confirm transposon integrations only, the sequencing primers were designed within
the long terminal repeat region of the piggyBac transposon integration site 5 bases upstream of
piggyBac integration site sequence (TTAA). PB5pr_seq_2:
5’-CACCGAGATCTACACCACGCATGATTATCTTTAACGTACGTCACAATATGATTATC
TTTC-3’ for the 3’ piggyBac sequence; PB3pr_seq_3: 5’-CACCGAGATCTACACATGCGTCA
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ATTTTACGCAGACTATCTTTC-3’ for the 5’ piggyBac sequence;
Spl_rev_seq: 5’-TAATACGACTCACTATAGGTGACAGCGAGCGCT-3’
for the reverse sequence; and Spl_tag_seq: 5’-AGCGCTCGCTGTCACCTATAGTGAGTCGTA
TTA-3’ to determine the index sequence for multiplexing (4). Since this meant all reads started
with the same 9 bases it interfered with Illumina’s template generation step. To skip template
generation in the 9 bp mono-template sequence, the standard Amplicon recipe was modified.
This modified recipe commenced the sequencing reaction with dark-cycles (cycles where
incorporation of bases but no imaging takes place). To confirm the sequence of these omitted
bases a separate transposon index read (index read 2) was added to the recipe. Even though this
solved sequencing issues in other CG neutral piggyBac libraries, the genomic AT bias in P.
falciparum resulted in Illumina’s colour matrix calling errors. To eradicate these errors, the
libraries were spiked with low (MiSeq: 10-20%) or higher (HiSeq: 50%) amounts of a welldefined CG neutral genomic library (i.e. PhiX) [4].”

QISeq Primary Sequence Analysis
All piggyBac mutants were generated in the strain NF54, while the P. falciparum
reference genome is generated from 3D7 (7). A reference genome of NF54 was therefore
generated to increase the accuracy of insertion site calling. Illumina libraries of 400-500bp
fragment length were generated using following the PCR-free protocol (9). An NF54 reference
genome was generated using a morphing approach with ICORN (16) transforming the 3D7
genome version 3 through iterative mapping and correcting into to the NF54 genome. As
reference we used the P. falciparum 3D7 reference from September of geneDB
(ftp://ftp.sanger.ac.uk/pub/project/pathogens/malaria2/3D7/3D7.latest_version/version3/2014/Se
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ptember_2014/). The NF54 reference genome generated can be found at
ftp://ftp.sanger.ac.uk/pub/project/pathogens/Plasmodium/falciparum/NF54/Assembly/V1_morph
ed. The QISeq libraries were sequenced on both a MiSeq and HiSeq2500, with 5’ and 3’ libraries
sequenced separately. Samples were multiplexed. The read length was 75 bp and the fragment
size around 350. These sequence reads were mapped to the NF54 reference genome.

QISeq Advanced Data Analysis
In analysing QISeq data for phenotypic effect of the heat shock, we compared relative
abundance in mapped reads of each mutant after heat shock relative to its control held at 37 C.
Changes of relative abundance represent a combined measure of a parasite’s growth, its
proportion in the starting population, and the fixed read number for each Illumina sequencing run.
Therefore to facilitate comparative analysis, the mapped sequence data were used to calculate a
representative Fold Change (FC) of growth with and without heat shock (Fig. 3.1B). Mutants
that are attenuated have a negative fitness score assigned to them, while those that are not have a
positive fitness score, indicating an excess amount of survivors in the pool (6). Fitness scores are
represented by fold change or log2 values between the input and output pools, where the total
number of reads for each transposon is compared (6). For strongly deficient mutants, sequence
reads were unable to be mapped in the output pool, thus the amount that went in was not
recoverable on the way out.
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Results
Development of a Heat Shock Screen for P. falciparum piggy Bac Mutants
using QISeq
Three piggyBac mutant pools of P. falciparum clones were combined into one master
pool and exposed to febrile temperature in order to test the effects of heat on the parasite. Table
3.1 lists the 126 mutants used in the heat shock assay of the master pool. The collection of
mutants tested had a wide diversity of GO pathways represented from conserved Plasmodium
proteins to those involved with transcription, metabolism, transport, etc. Growth at 37°C was
compared to that at 41°C, where fold change was plotted for each mutant. Phenotype screens
help to identify possible gene targets and QISeq can be used to confirm those phenotypes. The
introduction of next generation sequencing techniques, like QISeq, further enhances our ability
to discern gene function and observe their role in viability.

Febrile Temperature Exposure Impacts Growth of pooled piggyBac
Mutants
In this study successive rounds of heat shock mirror malaria paroxysm and affect the
growth and development of parasites with mutations in genes important for tolerating fever
during an infection. As anticipated, QISeq results revealed significant variations in growth of
among only some mutants in the master pool (Figure 3.3 A & B). Treatment cultures were
exposed to 41°C, an elevated temperature in the human host and control cultures were
maintained at normal body temperature or 37°C. Fold changes of mutant growth at control and
heat shock temperatures were compared over the course of the experiment. A positive value for
fold change was seen in the mutants on the left side of the bar graph and a negative fold change
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appears on the right side of figure 3.3 B. The sequence reads for mutants corresponded to their
growth over 24 cycles with a cutoff value of 100, and mutants above that or increasing in read
number are more abundant after heat shock.

Bioinformatics Reveal Functional Relationships between Mutants in
Pooled Screen
An in silico analysis of the piggyBac mutants in the pooled screen and the individual
screen was conducted to validate the heat shock phenotype through comparison of genes that are
sensitive or resistant to febrile temperatures (Figure 3.4). The heat shock response is mediated
by genes expressed at different life cycle stages of P. falciparum. There are gene clusters in
figure 3.4 with higher expression in sexual stages (gametocytes and ookinetes), such as those
involving LRR5 and IMC1b. These genes are also important in the parasite’s adaptation to heat
shock stress. Figure 3.5 shows the Gene Ontology (GO) annotations that identified functional
relationships between sets of proteins as performed with GO TERM Mapper
(http://go.princeton.edu/cgi-bin/GOTermMapper) and the PANTHER classification system
(http://www.pantherdb.org/). The pooled mutants that had a positive fold change or increased
growth after heat shock were largely dominated by genes of biochemical pathways and protein
metabolism. Also, conserved proteins of unknown function and export proteins were associated
with this group. The decreased growth mutants that had a more negative fold change consisted
of genes involved with transcription and nucleic acid metabolism.
The amino acid sequences of these proteins were used to find any conserved domains that
led to interaction data and predicted associations. Cytoscape software along with the GOlorize
plugin was used to develop network linkages between genes. An enrichment mapping
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application and the BINGO program allowed for the overrepresentation of a gene set in a
biological network based on GO terms so that the frequency of genes in a network was assessed
(Figure 3.6). Interestingly, the mutants in this phenotype screen were affiliated with a transport
and cellular homeostasis cluster. Genes involved with this cluster are heat shock genes or HSPs
and their chaperone complexes, which maintain cellular homeostasis under conditions of
temperature and heat stress. Other enriched genes were in clusters involved with gene
expression, ribosomal synthesis, RNA metabolism, and membrane transport.

Discussion
Understanding malaria fever and the genes involved in helping the parasite adapt to such
environmental conditions serve a dual purpose. Primarily, it provides new knowledge about
Plasmodium biology and secondly, it offers new avenues for drug discovery. The genes
associated with malaria fever are numerous and exist in various compartments of the cell (14).
By using QISeq, differentiation between mutants that were combined into one giant pool was
made. This technique found separate insertions corresponding to each individual mutant in the
pool. We were able to assess the effects of heat shock on P. falciparum parasites in a highthroughput manner.
In comparing the individual heat shock screen to the pooled assay, we found that both
techniques could produce a similar set of genes that were sensitive and resistant to febrile
temperature. Both assays agreed in identifying the extreme heat shock phenotypes. This was
evident when subjecting a group of individual mutants to heat shock three times as one of the
mutants PB-115 or PF3D7_1227800 continued to have decreased growth and exhibit the
sensitive heat shock phenotype. The genes that were resistant to heat shock stress included a
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PHISTa protein, var genes, an asparagine rich protein, and a repressor of RNA polymerase III
transcription. Those genes that had decreased growth or showed sensitivity to elevated
temperatures were enzymes such as histone S-adenosyl methyltransferase, Acyl-CoA synthetase,
RNA pseudouridylate synthase, protein phosphatase, a transcription factor with AP2 domains
and a leucine rich repeat protein. Conserved genes of unknown function were present in both
categories, however there was a consensus in genes that function in trafficking/signal
transduction, export, transcription, and protein modification. This discovery fits with the idea
that the parasite must export or modify certain proteins to survive fever. In the individual screen,
many of these genes associate with heat shock proteins that help maintain homeostasis during
stress or package proteins by folding or unfolding them in response to this condition.
From this study, we identified proteins important in the heat shock response such as heat
shock proteins, var genes, transport/export proteins, transcription factors, RNA binding proteins,
protein kinases, surface proteins, and conserved proteins of unknown function. The genes that
appear to be more abundant after exposure to febrile temperature consist of those affiliated with
nucleic acid metabolism and transcription regulation. The microarray expression data from the
Oakley 2011 study, revealed the upregulation and downregulation of many genes identified as
biomarkers for malaria fever (14). Our research looked at the functional protein level of some of
these genes exhibiting the heat shock phenotype. Many of the genes in our pooled screen that
differed from that study included additional heat shock proteins, histone S-adenosyl
methyltransferase, 40S and 60S ribosomal proteins, a duffy binding-like merozoite surface
protein, a nucleoside transporter, and trafficking proteins to name a few. This cadre of genes
continues to suggest that post-translational modification is altered in the parasite, along with the
remodeling of its membrane structure and transport mechanisms to provide protection during
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elevated temperature. Also, it is important to identify the insertion site of the piggyBac
transposon, as the phenotype seen may be related to its insertion in the middle of a functional
domain, as was the case with the var genes in the individual screen. Additional experiments
should be conducted to determine significance of the growth effect seen in these genes and if
functional associations can be made.
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Table 3.1: piggy Bac Mutant List for Pooled Heat Shock Assay. Red = Pool 1, Blue
= Pool 2, and Green = Pool 3. The mutants in these pools were combined into a master pool for
heat shock.
PB
ID

PlasmoDB ID

Gene
Start

Gene
End

Insertion
Site

Gene
Strand

1

PF3D7_0811300

567824

573148

568855

+

CCR4-associated factor 1 (CAF1)

2

PF3D7_1305500

271411

273726

271629

+

3

PF3D7_0615900

662435

667855

667365

-

4

PF3D7_1122900

878969

895273

879695

+

Mitogen-activated protein kinase
phosphatase 1, putative (MKP1)
Conserved Plasmodium protein,
unknown function
Dynein heavy chain, putative

5

PF3D7_1141900

1676255

1677769

1676856

-

6

PF3D7_1475700

3117392

3118951

3116484

+

7

PF3D7_0211100

451751

455116

451759

+

8

PF3D7_0203000

141625

147564

142289

-

9

PF3D7_0404600

247731

260147

250802

+

10.1

PF3D7_0400100

28706

37677

34709

+

10.2

PF3D7_0627900

1119587

1120858

1119286

+

11

PF3D7_0416500

723073

724242

724234

-

12

PF3D7_1018300

729809

732856

733690

-

13

PF3D7_1360200

2406838

2408385

2406699

-

14

PF3D7_0511500

486602

516787

516248

+

15

PF3D7_0611800

490858

501140

498591

-

16.1

PF3D7_0619900

840523

841224

841186

+

16.2

PF3D7_0532000

1292410

1296199

1296386

+

17

PF3D7_0521900

888657

895144

889784

+

18

PF3D7_1219300

766654

774197

769606

-

19

PF3D7_1133700

1302173

1305987

1302725

+

20

PF3D7_0808700

440408

448062

446344

+

21

PF3D7_1136000

1403906

1414512

1404540

+

22

PF3D7_0931000

1248866

1251601

1250793

-

23

PF3D7_0830900

1317600

1318341

1318070

-

24

PF3D7_1231800

1314696

1320170

1319997

+

25

PF3D7_1035800

1420533

1422671

1422622

+

26

PF3D7_1444100

1801961

1825326

1812894

-

28

PF3D7_1138900

1540804

1544163

1544148

+

29

PF3D7_1441800

1702609

1703809

1703121

-
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Gene Description

Inner membrane complex protein 1b,
putative (IMC1b)
Tubulin epsilon chain, putative
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium membrane
protein, unknown function
Erythrocyte membrane protein 1,
PfEMP1 (VAR)
Ribonuclease P protein subunit p29,
putative (POP4)
Repressor of RNA polymerase III
transcription MAF1, putative
Conserved Plasmodium protein,
unknown function
Conserved protein, unknown function
RNA pseudouridylate synthase,
putative
Conserved Plasmodium protein,
unknown function
Splicing factor 3A subunit 2, putative
(SF3A2)
28S ribosomal RNA
Conserved Plasmodium protein,
unknown function
Erythrocyte membrane protein 1,
PfEMP1 (VAR)
Conserved Plasmodium protein,
unknown function
Erythrocyte membrane protein 1,
PfEMP1 (VAR)
Conserved Plasmodium protein,
unknown function
Elongation factor Tu, putative
Plasmodium exported protein,
unknown function
Asparagine-rich protein, putative
Probable protein, unknown function
(M712)
Conserved Plasmodium protein,
unknown function
Unspecified product
Vacuolar-sorting protein SNF7,
putative

Table 3.1: (Continued)
PB
ID

PlasmoDB ID

Gene
Start

Gene
End

Insertion
Site

Gene
Strand

30

PF3D7_1345800

1831842

1834991

1833303

+

31

PF3D7_1432400

1275899

1282645

1281184

-

32

PF3D7_0819800

891658

898502

896251

-

33

PF3D7_1207800

354540

357446

356310

-

34

PF3D7_1143500

1737256

1740029

1739772

-

35

PF3D7_1001700

92573

93526

92206

-

36

PF3D7_1019400

786503

787008

787283

+

37

PF3D7_1311900

507900

509735

510072

+

38

PF3D7_1035700

1413200

1415293

1417438

+

39

PF3D7_1103100

140048

140801

141915

-

40

PF3D7_0815000

709333

710600

710781

-

42

PF3D7_1216100

646979

647860

648182

+

43

PF3D7_0206100

245358

246699

246992

+

45

PF3D7_1227000

1092160

1092651

1092023

-

48

PF3D7_1344000

1759466

1761991

1758853

+

49

PF3D7_1328700

1213394

1213615

1212674

+

50

PF3D7_1138800

1533252

1539856

1532518

-

51

PF3D7_1327100

1138558

1141561

1138368

-

52

PF3D7_1136600

1441503

1445471

1445642

+

53.1

PF3D7_1200600

46788

56805

46222

-

53.2

PF3D7_0900800

52648

54020

52076

-

54

PF3D7_0902200

98175

100339

99320

-

55

PF3D7_0727200

1156748

1158409

1156274

-

56

PF3D7_0105500

228485

229519

229890

-

57

PF3D7_1126200

1023790

1024496

1023203

-

Conserved Plasmodium protein,
unknown function
40S ribosomal protein S18, putative

58

PF3D7_1343700

1724817

1726997

1728031

-

Kelch protein K13 (K13)

59.1

PF3D7_1426400

1026262

1027144

1027315

-

MORN repeat protein, putative

59.2

PF3D7_0606000

250612

253803

253811

-

60

PF3D7_1330500

1284988

1287165

1284702

+

61

PF3D7_1342900

1682393

1693969

1694959

-

62

PF3D7_1302000

112792

113815

115505

-

Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Transcription factor with AP2
domain(s) (ApiAP2)
EMP1-trafficking protein (PTP6)

63

PF3D7_0203600

166144

168051

168158

+

65

Gene Description
Conserved Plasmodium protein,
unknown function
Leucine-rich repeat protein (LRR5)
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Plasmodium exported protein
(PHISTc), unknown function
60S ribosomal protein L30e, putative
Vacuolar ATP synthase subunit a
(vapA)
Duffy binding-like merozoite surface
protein (DBLMSP)
60S acidic ribosomal protein P1,
putative (RPP1)
Selenoprotein (Sel3)
Conserved Plasmodium membrane
protein, unknown function
Cysteine desulfuration protein SufE
(SufE)
Conserved Plasmodium protein,
unknown function
Aminomethyltransferase, putative
Plasmodium RNA of unknown function
RUF1
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Erythrocyte membrane protein 1,
PfEMP1 (VAR2CSA)
Erythrocyte membrane protein 1
(PfEMP1), exon 2, pseudogene (VAR)
Serine/threonine protein kinase, FIKK
family (FIKK9.3)
Cysteine desulfurase, putative (NFS)

Conserved Plasmodium protein,
unknown function

Table 3.1: (Continued)
PB
ID

PlasmoDB ID

Gene
Start

Gene
End

Insertion
Site

Gene
Strand

64

PF3D7_1108000

352556

354262

351780

+

IWS1-like protein, putative

65

PF3D7_0606000

250612

253803

253817

-

66

PF3D7_0614500

606142

607259

607866

-

Conserved Plasmodium protein,
unknown function
60S ribosomal protein L19 (RPL19)

67

PF3D7_0203700

168682

170136

170489

-

68

PF3D7_0601900

78190

78784

77404

+

69.1

PF3D7_0524400

1013453

1014550

1012936

-

69.2

PF3D7_0612800

528060

529175

530075

-

71

PF3D7_1001900

99379

100361

100751

-

72

PF3D7_1409500

370146

373006

373820

+

74

PF3D7_0402000

114601

116058

116369

-

76

PF3D7_1433400

1312304

1329577

1330867

-

77

PF3D7_0322100

930640

932415

930071

-

Plasmodium exported protein (hyp16),
unknown function (PfJ23)
Conserved Plasmodium protein,
unknown function
Plasmodium exported protein
(PHISTa), unknown function
Conserved Plasmodium membrane
protein, unknown function
RNA triphosphatase (Prt1)

78

PF3D7_0623900

977183

978049

979252

+

Ribonuclease H2 subunit A, putative

79.1

PF3D7_0103300

143640

146396

146981

-

79.2

PF3D7_1434200

1368815

1369796

1370157

-

Conserved Plasmodium protein,
unknown function
Calmodulin (CAM)

80

PF3D7_1013600

533109

539825

532345

+

81

PF3D7_1350500

2015367

2018801

2020022

-

82

PF3D7_1206800

308214

310397

306444

+

83

PF3D7_1406900

251059

252826

249419

+

84

PF3D7_1221000

836912

843901

845511

-

85

PF3D7_0916700

696863

698029

699679

-

87

PF3D7_0812500

626069

628945

625232

-

Histone-lysine N-methyltransferase,
H3 lysine-4 specific (SET10)
RNA-binding protein musashi, putative
(HoMu)
RNA-binding protein, putative

91

PF3D7_1433900

1360002

1364558

1359496

+

Protein kinase, putative

92

PF3D7_0414600

658620

659538

659953

-

Conserved protein, unknown function

94

PF3D7_0110500

396591

403606

395817

+

Bromodomain protein, putative

95

PF3D7_0202100

109564

110580

109046

-

96

PF3D7_1207300

343326

344361

342678

-

97

PF3D7_0405400

291251

300976

290343

+

98

PF3D7_0807600

389596

394259

389064

-

99

PF3D7_1347200

1889853

1891121

1891837

-

Plasmodium exported protein
(PHISTc), unknown function, liver
stage associated protein 2 (LSAP2)
Conserved Plasmodium protein,
unknown function
Pre-mRNA-processing-splicing factor
8, putative (PRPF8)
Conserved Plasmodium protein,
unknown function
Nucleoside transporter 1 (NT1)

100

PF3D7_1430000

1181664

1182982

1182677

-

101

PF3D7_0312400

524154

526439

527173

-

66

Gene Description

Nucleolar preribosomal assembly
protein, putative
Conserved Plasmodium protein,
unknown function
Cytosolic preribosomal GTP-binding
protein, putative
6-cysteine protein (P12p)

Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Radical SAM protein, putative

Conserved Plasmodium protein,
unknown function
Glycogen synthase kinase 3 (GSK3)

Table 3.1: (Continued)
PB
ID

PlasmoDB ID

Gene
Start

Gene
End

Insertion
Site

Gene
Strand

102

PF3D7_1316000

668360

670745

672107

-

Protein kinase, putative

103

PF3D7_0604400

184892

185843

186830

+

104

PF3D7_0104200

182822

184222

186648

-

Conserved Plasmodium protein,
unknown function
StAR-related lipid transfer protein

105

PF3D7_1333400

1370083

1370799

1369625

+

Conserved protein, unknown function

106

PF3D7_1139300

1556744

1565045

1567137

-

107

PF3D7_0505100

220839

229253

220076

+

108

PF3D7_1252300

2128400

2128786

2131213

-

109

PF3D7_1452500

2151823

2153614

2154633

-

Transcription factor with AP2
domain(s) (ApiAP2)
Trafficking protein particle complex
subunit 8, putative (TRS85)
Conserved Plasmodium protein,
unknown function
SNARE protein, putative (BET1)

110

PF3D7_0937800

1495579

1503336

1507053

-

111

PF3D7_1004600

215717

219759

216125

+

112

PF3D7_0731000

1333175

1334938

1336930

-

114

PF3D7_0632800

1374797

1382627

1373882

-

115

PF3D7_1227800

1134370

1137648

1137689

-

116.
1
116.
2
119

PF3D7_1436200

1467629

1474438

1476670

-

PF3D7_0920300

831669

832648

831572

+

PF3D7_0630100

1254907

1256940

1257230

-

120

PF3D7_1459500

2436695

2439616

2436451

+

121

PF3D7_0523200

966123

969737

965601

+

122

PF3D7_0726000

1086570

1090357

1090517

+

123

447923

449968

450635

-

124

PF3D7_1411100.
1
PF3D7_0731600

1368161

1370596

1367266

+

125

PF3D7_0622900

925105

931074

933481

-

126

PF3D7_1334800

1413102

1413947

1412492

-
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Gene Description

Erythrocyte membrane protein 1,
PfEMP1 (VAR)
Conserved Plasmodium membrane
protein, unknown function
Unspecified product, ncRNA
Erythrocyte membrane protein 1,
PfEMP1 (VAR)
Histone S-adenosyl
methyltransferase, putative
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
Conserved Plasmodium protein,
unknown function
28S ribosomal RNA
Conserved Plasmodium membrane
protein, unknown function
Acyl-CoA synthetase (ACS5)
Transcription factor with AP2
domain(s), putative (ApiAP2)
MSP7-like protein (MSRP2)

A

B

Fold _ change =

Percentageheat!shock ( pb ! muti )
Percentagecontrol ( pb ! muti )

Figure 3.1: Pooled Heat Shock Assay. A. Flow diagram of assay method using multiple
pools of piggyBac mutants. B. The equation used in calculation of fold change for QISeq
analysis.
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Figure 3.2: QISeq Library Construction. Overview of the library generation process in
which piggyBac gDNA is sheared, and independent libraries are sequenced using a specific
Illumina protocol. This image was adapted from figure 1 in Bronner et. al., “Manuscript in
preparation” (4).
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A

B

Figure 3.3: Heat Shock Results on Pooled Mutants. A. Representations of parasite
abundance as percentage within a pie chart. B. QISeq analysis of pooled mutants showing fold
change growth when comparing febrile temperatures to controls. Fold changes of other
replicates are ranked high to low according to the order of replicate 1.
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Figure 3.4: Heat Shock Co-expression Network of Pooled Mutants. The mutants in
this network are generated using the expression correlation with Pearson's R at larger than 0.80
(as provided by Dr. Rays Jiang & Dr. Charley Wang at the University of South Florida). The
thickness of the edges represents the level of expression correlations between two given genes.
The heat shock winners (resistant, red circles) or losers (susceptible, blue circles) do not show a
specific expression pattern, because they are in all major clusters. Mutants with a large
phenotype score or fold change are represented with larger circles.
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Figure 3.5: Graph of GO Categories for Pooled Heat Shock Screen. This bar graph
represents the Gene Ontology or GO terms associated with some of the mutants detected in the
large pool.
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Figure 3.6: Pooled Screen Enrichment Map. The image above categorizes the piggyBac
mutants under heat shock by cellular compartment and various biological processes. GO terms
were used to make this enrichment map. Red node size corresponds to the number of genes
linked to that GO term. The green edge size corresponds to the number of genes that overlap in
GO terms.
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CHAPTER FOUR:
PHENOTYPIC CHARACTERIZATION OF THE PLA SMODIUM FA LCIPA RUM
NOT1 MUTANT (PF3D7_1103800)

Introduction
The protozoan parasite Plasmodium falciparum, which is the most important causative
agent of malaria, causes a debilitating disease responsible for a million deaths globally. More
than 124-283 million clinical cases are reported annually, of which most are young children (13).
Falciparum malaria can lead to the severe clinical complications seen in patients from Africa and
other endemic countries. Once these parasites enter the body, they initially proceed to the liver,
where they develop and proliferate before moving on to the red blood cells. Pregnant women are
disproportionately affected, but with preventative therapy and seasonal prophylaxis morbidity
and mortality can be reduced. However, widespread resistance to anti-malarial drugs is
emerging as a major health threat, promoting the need for new drug discovery and development
projects. Core metabolic functions represent attractive new drug targets, since it is expected that
these functions may be less likely to develop resistance mechanisms without deleterious effect
on the parasite.
Regulation of cell cycle development in the parasite is largely a response to their
environment in which post-translational modifications occur at critical checkpoints during their
48-hour life cycle. According to the Central Dogma of Biology, gene expression flows from
DNA to RNA to proteins and control of transcription and translation is vital to parasite survival.
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Post-transcriptional control takes place in the nucleus, where RNA binds to proteins that form
ribonucleoprotein particles and subsequently transports it to the cytoplasm for further processing
(5). Translational amplification or a high level of mRNA synthesis is also important to stability,
since cell cycle defects may occur if there is dysregulation of mRNAs (5, 10). Previous studies
in the Adams lab using piggyBac insertional mutagenesis identified the carbon catabolite
repressor protein 4 (CCR4) – associated factor 1 (ΔCAF1) is a critical regulator of expression for
a subset of P. falciparum genes, especially genes expressed late in schizonts. The genome of the
CAF1 clone was sequenced at Sanger, confirming its mutant phenotype was not due to SNPs,
INDELs or other unrelated genomic mutations (4). CAF1 is a component in the CCR4-NOT
complex in which the major subunit is the Negative On TATA-less promoters protein (NOT1)
and acts as a major scaffold holding each subunit together (Figure 4.1A). By extending this
discovery to another member of the CCR4-NOT complex, NOT1, we can begin to understand
the role of such genes in mRNA metabolism and parasite development.
The CCR4-NOT complex participates in various facets of mRNA synthesis, such as the
activation and repression of mRNA initiation, mRNA elongation and degradation. In addition to
NOT1, there are four other NOT proteins in the CCR4-NOT complex that act as translational
repressors in the model organism of yeast (6). NOT family members block the attachment of
TATA binding proteins to genes that lack the TATA promoter with the NOT2-NOT5 binding
site in the C-terminal position and the CCR4-CAF1 binding site located at the N-terminus
(Figure 4.1B, [1]). The other members of the complex function in ubiquitination and histone
acetylation, important processes in the regulation of transcription. Cells lacking NOT1 or CAF1
have reduced mRNA degradation efficiency and collectively, all members may function as a type
of chaperone complex (7). In other organisms like Caenorhabditis elegans, NOT1 is important in
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microtubule and spindle formation and CAF1 participates in somatic cell development (7). In
yeast, a knockout of NOT1 cannot be generated indicating that it is the only component of the
CCR4-NOT complex essential for viability (12).
Much about the function of NOT1 in Plasmodium is unknown, yet the NOT1 domain is a
conserved motif. Studies in P.berghei have shown that this protein complex is necessary for
female gametocyte maturation as P bodies function in translational repression and mRNA
stability (9). In earlier studies with the ΔNOT1 clone, a 50% decrease in growth was observed
compared to the wild-type control (unpublished data). As seen with the effects of the ΔCAF1
parasite, we hypothesize that the ΔNOT1 clone will also have a delay in invasion due to its slow
growth phenotype. This chapter is a basic study analyzing the ΔNOT1 mutant for distinct
phenotypic changes observed in the ΔCAF1 parasite.

Materials and Methods
Plasmodium falciparum Cell Culture
The malaria parasite cultures were grown and maintained using standard methods from
the MR4 manual. Mutants of not1 and caf1 were previously made using the piggyBac
transposon through transfection of P. falciparum NF54 with infected RBCs ‘preloaded’ with
plasmid DNA (2, 3). To ensure parasite invasion of only plasmid-loaded RBCs, mature bloodstage parasites were purified on a MACS magnetic column (Miltenyi Biotec); 1 million purified
parasites were added to erythrocytes loaded with 100 µg of the transposon plasmid and 50 mg of
the transposase plasmid to start a 5 ml parasite culture. Individual mutant clones were obtained
by limiting dilution of parasites post-drug selection. All clones were cultured at 37°C with
mixed gas (5% O2, 5% CO2, and nitrogen) and 5% hematocrit (O+ blood from the Interstate
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Blood Bank) in complete media. The growth media contained RPMI 1640 from Invitrogen
supplemented with 0.5% Albumax II (Invitrogen), 0.25% sodium bicarbonate, and 0.01 mg/mL
gentamicin.

Bioinformatics Analyses of piggy Bac Mutants
For comparative sequence analysis of NOT1, in silico data was gathered for
PF3D7_1103800. Initially, the deduced PF3D7_1103800 amino acid sequence was compared to
the NOT1 sequences identified in Plasmodium spp., other Apicomplexa and eukaryotes.
Sequence information was obtained from the NCBI BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and SMART databases (http://smart.emblheidelberg.de/). Amino acid alignments were carried out in order to generate a multiple
sequence alignment, using the Clustal W Multiple alignment editor, BioEdit,
(http://jwbrown.mbio.ncsu.edu/BioEdit/bioedit.html) and MacVector® 10.5.1, as well as MEGA
software version 5.01 (http://www.megasoftware.net/). The aligned amino acid sequences were
used to construct a neighbor-joining tree. This method used 1000 replicates for the bootstrap
values, which determined phylogenetic relatedness. MEGA software was also employed to
calculate evolutionary distance by the p-distance method along with constructing trees.

Microarray Analysis
Similar to the analysis of the PF3D7_0811300 CAF1 mutant, RNA extracts were
collected from PF3D7_1103800 NOT1 mutant cultures at six time points (ER – early ring, LR –
late ring, ET – early trophozoite, LT – late trophozoite, ES – early schizont, and LS – late
schizont). This allows us to examine the expression of the NOT1 mutant PF3D7_1103800 (E5)
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and compare it with the CAF1 (F3) mutant and WT microarray expression data of the parent
strain NF54. The samples were analyzed in Dr. Julian Rayner’s lab at the Wellcome Trust
Sanger Institute by Dr. Alena Pance, who statistically adjusted the RNA expression levels for
evaluation of microarray data. Log-transformed ratios of ΔNOT1, ΔCAF1, and WT values were
provided with a cutoff greater than 1 denoting increased expression and <-1 denoting decreased
expression (4).

Western Blot Analysis
Parasite cultures of NF54 WT and the NOT1 mutant were synchronized twice with 5%
sorbitol (once at 0-8 hours post-invasion and again 8-12 hours later during the ring stage) at high
parasitemia of at least 5-8%. The parasites were analyzed every 2 hours at mid-trophozoite stage
until the late schizont stage or end of the cycle (32 hrs. – 48 hrs.). To start, 120 mL cultures
were used and at each timepoint, the parasites were magnetically purified through a MACS
column. The effluent was centrifuged, siphoned off leaving only the pellet, and washed once in
1X PBS. 15% saponin in PBS (made fresh) was diluted to a final concentration of 0.15% and
added to the pellet for a 10 minute incubation on ice in order to remove the red blood cell protein.
The parasites were centrifuged at 2,000 x g for 5 minutes with removal of the supernatant and
washed in ice-cold 1X PBS (3 times). The pellet was resuspended in 1X PBS with protease
inhibitor cocktail (Sigma) and centrifuged at 4°C for 5 minutes. The supernatant was removed,
and the pellet was resuspended in 2X SDS-PAGE sample buffer with boiling at 65°C for 5
minutes. The samples were stored at -80C until separation on a 4-12% NuPAGE precast gel
(Invitrogen) and then transferred to a nitrocellulose membrane. The primary antibody dilutions
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for the erythrocyte binding antigen-175 (EBA-175) and the glideosome-associated protein 45
(GAP45) were 1:1000 for both in order to probe the membrane.

Immunofluorescence Assays
The parasites are synchronized and purified at the schizont stage in preparation for the
IFAs or immunofluorescence assays. Infected parasites are counted using a hemocytometer and
light microscope. The magnetically purified schizonts were smeared on a glass slide, fixed
overnight in 4% paraformaldehyde and 0.0075% glutaraldehyde in RPMI medium. The slides
were subsequently permeabilized in 1% Triton X-100 in PBS for 15 min., blocked in 3% BSA or
bovine serum albumin for 1 hour at room temperature (RT). A primary antibody dilution of
1:100 was added to 3% BSA and incubation occurred at RT for 1 hour. After multiple washes
with PBS, the parasites were incubated with a 1:1000 dilution in PBS for 1 hour at RT. With the
addition of Hoechst (1:1000) for DNA staining and allophycocyanin (APC)-conjugated antiglycophorin A antibody (2 µg/mL) for red cell membrane staining, the parasites were incubated
for 30 to 45 minutes in the dark at RT. Antibodies to EBA-175, MSP-1, and GAP45 (generously
provided by Dr. Julian Rayner’s group) were used in the experiment. The parasites were washed
in 1X PBS and suspended in mounting media (Fluormount G, Southern Biotech cat# 0100-01),
covered and sealed for visualization.

Live Video Microscopy
Late stage schizonts were magnetically purified at high parasitemia, placed on a glass
slide or a poly-L-lysine-coated Petri plate and viewed with a DeltaVision CORE microscope
(Applied Precision). The schizonts were doubly-labeled with Hoechst (10 µg /mL) 33342 and
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allophycocyanin (APC)-conjugated anti-glycophorin A antibody (2 µg/mL) for 10 – 15 minutes
at RT in the dark. Afterwards, the parasites were washed in 1X PBS and covered for microscopy,
where time-lapse video was taken.

Results
Phylogenetic Analysis of the NOT1 Domain Shows Conservation among
Plasmodium
There are two genes in the P. falciparum genome coding for deduced NOT1 proteins with
sequence homology to yeast and microarray data indicates both not1 genes are co-expressed in
all stages (8, 11). The amino acid sequence alignments reveal that the NOT1 domain is
conserved among Plasmodium and other eukaryotes (Figure 4.2). NOT1 has been analyzed
phylogenetically and the neighbor-joining tree infers a not1 gene duplication event between both
NOT1 proteins, PF3D7_1103800 NOT1a & PF3D7_1417200 NOT1b (Figure 4.3). These data,
together with the observation of a low sequence identity between Apicomplexa and other species
support the hypothesis that NOT1 proteins have evolved to have distinct functions even though
other subunits of the complex are single copy. The attenuated growth resulting from the
disruption of the PF3D7_1103800 NOT1a indicates that PF3D7_1417200 NOT1b cannot
compensate for this loss of function, supporting the hypothesis that these scaffold proteins have
at least some distinct functional roles required for the parasite’s intraerythrocytic growth and
development.
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Parasite Gene Expression is Affected in the not1 Mutant
Changes in gene expression occur when not1 is disrupted with the piggyBac insertion
(Figure 4.1B). The expression profiles of the ΔNOT1 parasite, NF54 WT, and ΔCAF1 were
compared during ring, trophozoite, and schizont stages. There were minor differences shown in
the heat map of the mutant parasite lines but major differences compared to the WT parent.
There is also increased abundance at the ring stages of transcript for microneme proteins (EBA175) and surface proteins (MSP-1) for the mutants. Motility proteins such as GAP45 have
decreased expression in the ΔNOT1 compared to the wild-type in late schizont and early ring
stages (Figure 4.4). Immunoblot analysis of trophozoite to schizont stages demonstrated the
early or mis-timed expression of invasion-related proteins (GAP45 and EBA-175) in the NOT1
mutant (Figure 4.5). These proteins are customarily expressed in the late schizont stage of WT
parasites.

Variation in Localization of Blood-Stage Proteins
In the trophozoite and schizont stages for ΔNOT1, EBA-175 appears to present sooner in
development and has a surface localization similar to Caf1 mutant cultures along the merozoites.
Yet, EBA-175 is detected at the apical ends of merozoites in the NF54 WT strain (Figure 4.6).
Typically, GAP45 is located around the membrane of schizonts or invading merozoites and is
stained with a corresponding fluorophore. GAP45 localizes to the parasite membrane in both the
WT and ΔNOT1 schizonts. MSP-1 also exhibits the same localization pattern between the
mutant and wild-type, as it localizes around the merozoites or parasite nuclei.
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NOT1 Mutant Parasites Show Similar Aberration in Egress to caf1
Mutants
The mutant and wild-type parasites were observed at the end of the blood stage by live
video microscopy of magnetically purified schizonts. Since the ΔNOT1 has a reduced fold
change in growth compared to the NF54 WT, the phenotype of the mutant was expected to
demonstrate a noticeable effect in late schizogony. Images under differential interference
contrast (DIC) microscopy reveal select schizont clusters (grape-like formation), which may
result in a delayed burst or release of merozoites (Figure 4.7). This was similar to the
dysfunctional egress observed in previous studies with the CAF1 mutant, where schizont rupture
was hindered (4).

Discussion
Forward genetic screens that utilize insertional mutagenesis techniques like the piggyBac
system offer insight into the parasite’s genome and the function of potentially important genes.
One of the genes in that mutant library is NOT1 and it has a role in mRNA degradation along
with the deadenylase, CAF1. Both genes are apart of the CCR4-NOT complex, which helps
regulate gene expression in eukaryotes. Control of gene expression is vital for parasite
development and survival. Previously, a CAF1 mutant was shown to have an aberrant egress
function, delaying schizogony. As the two genes are connected in the CCR4-NOT complex, a
similar approach to characterization was used with NOT1 to determine its function.
The Plasmodium falciparum NOT1 gene shows a constitutive expression pattern with
possible variation in asexual stage expression. The analysis of the genome revealed that two
forms of NOT1 exist in Plasmodium species. Other eukaryotes have one not1 gene and in yeast,
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it is unable to be knocked out and remains essential for cell viability. The second NOT1 may
compensate for the other if disrupted, enabling the life cycle to continue unabated. The gene
itself appears to act as a bridge connecting the other members of the complex, taking on certain
attributes of its neighbors due to the binding sites present in its structure. Our results show that
the ΔNOT1 has altered localization with EBA-175 and mis-timed expression of invasion related
genes, similar to the ΔCAF1. This type of characterization may identify checkpoints of
vulnerability among the intraerythrocytic cycle in malaria. The major discovery of this study is
that the two NOT1 proteins of P. falciparum have distinct functional roles important for asexual
intraerythrocytic growth and development.
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A

B

Figure 4.1: CCR4-NOT Complex. A. This diagram shows the arrangement of CCR4-NOT
proteins in malaria. The NOT1 protein is the largest and is flanked by other members in the
complex. Image adapted from http://mpmp.huji.ac.il//maps/CCR4.html. B. A schematic of not1
disruption showing piggyBac repeats ITR1 and ITR2 flanking hdfr.
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Figure 4.2: NOT1 Domain Alignment. The C-terminal portion of the NOT1 domain is
aligned with the amino acid sequences of other proteins. Conserved and similar residues are
shaded in grey and black, respectively.
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Figure 4.3: Phylogenetic Analysis of the NOT1 Domain. The neighbor-joining tree
represents the phylogenetic analysis of sequences in the alignment of the full NOT1 domain.
The scale bar represents 0.05 amino acid substitutions per site. PF3D7_1103800 or NOT1 A is
highlighted in red and PF3D7_1417200 (NOT1 B) is highlighted in blue.
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Figure 4.4: Gene Expression Heat Map. The microarray analysis compares the
expression levels of invasion and surface proteins in the NOT1 mutant and NF54 WT parasites.
Increased expression is shown in yellow and decreased expression is blue.
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Figure 4.5: Expression of Invasion-related Proteins in the ΔNOT1 and WT. The
immunoblot analysis depicts protein expression of EBA-175 and GAP45 between the wild-type
and mutant.
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Figure 4.6: Immunofluorescence of Parasite Proteins in WT and ΔNOT1
cultures. The IFA with MSP-1, EBA-175, and GAP45 antibodies reveals a localization pattern
between mutant and WT cultures. Nuclei are stained with Hoechst/DAPI (blue), EBA-175,
MSP-1, and GAP45 (FITC, green), and the red blood cell membrane is stained red with antiglycophorin A.
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Figure 4.7: Snapshots from Live Video Microscopy depicting the NOT1 Mutant
Phenotype. These images display the delayed invasion or egress phenotype of the ΔNOT1
parasite during the late schizont stage as egress is altered. From Left to Right: Initial time point,
15 minutes later, and 30 minutes after that.
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CHAPTER FIVE:
SUMMARY

Conclusions
Heat Shock Assay Development
Fever is one of the hallmark symptoms of malaria and people living in endemic regions
of the world must receive proper treatment if their diagnostic test or blood smear comes back
positive. Left unchecked, uncomplicated malaria can become complicated or severe, where the
symptoms range from respiratory distress, acute anemia, organ failure to death. A rise in body
temperature during infection is the host’s way of defending itself. This is a necessary immune
function that inhibits the growth of malaria parasites. The purpose of this study was to expand
our current views on fever by identifying genes in the Plasmodium developmental cycle that
could be either impervious or vulnerable to elevated temperatures. Such a discovery would
allow for the development of drugs targeting invasion and replication. After all, it is the quick
release of merozoites from the depleted red blood cell that initiate the fever response.
The assay evolved from the concept that febrile episodes are cyclical and occur every 48
hours, the length of the erythrocyte cycle in P. falciparum. Zero to 24 hours post invasion is the
typical duration of the ring stage and it is here that febrile temperature is applied to in vitro
cultures of wild-type and mutant clones. This increase in temperature effectively synchronizes
the ring-stage parasites, while also preventing the further maturation of trophozoites and
schizonts (4, 5). The piggyBac mutant library provides us with a source of genetically altered
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parasites whose function can be elucidated through advanced sequencing methods like QISeq or
individual phenotype screens. The heat shock occurred over 8 hours at 41°C until the parasite
cultures were placed back at 37°C, akin to the fever breaking and near normal body temperatures
being restored.
For the first heat shock experiment in Chapter 2, one round of heat shock was used and
mutants were assessed individually similar to the Oakley study (5) that served as a model for our
experimental design. In our study mutants were subjected to 8 hours of heat shock and allowed
to recover at 37°C until the end of the cycle, 30 hours later. At this stage, schizont populations
were counted and growth rate compared. Some parasites did proceed to the next cycle of rings,
however that measurement may introduce another phenotype, delayed-death. This exhibits a
more pronounced growth inhibition in the next cycle and is usually a response to drug treatment.
In the second experimental study using collections of pooled mutants, three rounds of heat shock
took place every 48 hours over a period of 8 days, where growth between control and treated
pooled samples was compared. QISeq sequencing revealed that some parasites out-competed
others and were more abundant in the pool after heat shock or were able to survive over other
clones. The mutants that were more successful in the pool functioned in transcription, protein
modification, membrane/structural organization, and nucleic acid metabolism.
In results with both types of the piggyBac mutants tested by heat, only a few showed a
significant increase in growth compared to numerous mutations that increased sensitivity to fever.
This result suggests that few factors are actually can enhance a parasite’s growth to fever while
there are quite a few that help the parasite tolerate fever. In terms of drug discovery of new
targets the genes associated with mutant clones that were significantly decreased may represent
suitable drug targets as they function to protect parasites from febrile temperatures. Many of
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these genes were affiliated with pathways of RNA degradation, pathogenesis or invasion, the
spliceosome, endocytosis, and fatty acid metabolism. Furthermore, mutants of consideration for
drug discovery would be those whose growth affect is only due to heat shock. The attenuation
category was provided for these mutants as part of an earlier growth screen at 37°C (2). If they
were originally non-attenuated at 37°C and subsequently attenuated either positively or
negatively after heat shock, they could prove important in affecting the growth and development
of P. falciparum parasites.

Partial Characterization of the NOT1 mutant
The phenotypic characterization of the NOT1 mutant was the continuation of work
previously conducted on the CAF1 knockout. NOT1 and CAF1 are both members of the CCR4NOT complex, which is responsible for mRNA degradation and translational repression. Like
most protein complexes, it is multi-faceted and functions in many ways. Our goal was to
determine the function of NOT1 in P. falciparum. Sequence alignment revealed a conserved
NOT1 domain and similarity to other Plasmodium species. Additionally, there are two NOT1s
present in the malaria parasite and they seem to be expressed together. Not all of the members of
the complex have duplicate status, so a functionally distinct CCR4-NOT complex may not exist.
However, determining the role of the larger not1 gene (NOT1 B) may be the subject of a followup study if a gene knockout could be made with NOT1 A or PF3D7_1103800. All together,
NOT1 acts as a scaffold and exhibits some gene expression and localization behavior similar to
CAF1 when the gene is disrupted, causing delayed egress (3).
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Future Studies
The host-parasite relationship is complex and involves many factors, some environmental
and others genetic. While the race to find the answer for anti-malarial drug resistance continues,
researchers must look at every avenue of human and parasite biology. In the genetics defense
realm, sickle cell and other blood disorders confer protection against malaria. Sickle-cell
heterozygotes or patients that have sickle-cell trait (one abnormal hemoglobin gene) have a
better chance of survival during seasons of P. falciparum malaria transmission [1]. This level of
innate resistance along with the other hemoglobinopathies offers some relief from the parasite
load as does the human fever response. More mutants in the piggyBac library will need to be
screened for the heat shock phenotype and possibly complemented to test the rescue of growth
similar to the wild-type. The generation of possible drug targets is ideal for combating malaria
as chemical compounds will need to be tested for efficacy through a drug screen.
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